Document:

EX-10.3

 Exhibit 10.3 

CERTAIN CONFIDENTIAL INFORMATION INDICATED BY “[***]” HAS BEEN OMITTED FROM THE FILED COPY OF THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT
MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
 Confidential 

Share Subscription Facility Agreement 
 dated as of
January 20, 2021 
 by and among 
 RELIEF THERAPEUTICS
Holding SA    (the Company) 
 Avenue de Secheron 15 

1202 Geneve 
 Switzerland 

and 
 GEM Global Yield LLC SCS    (the
Purchaser) 
 412F, route d’Esch 2086 
 Luxembourg 

Luxembourg 
 and 

GEM Yield Bahamas Ltd    (GEMYB) 
 Office of
Lennox Paton Corporate Services 
 Limited 
 Bayside Executive
Park 
 Building 3 
 West Bay Street 

P.O. Box N-4875 
 Nassau

 Island of New Providence 
 Commonwealth of the Bahamas
    (the Company, the Purchaser and GEMYB each a Party and together the Parties) 

 Table of Contents 

 

									
	 Whereas
	  	 	1	 
	 1.
	  	Definitions and References	  	 	1	 
	 2.
	  	Subscription Notice	  	 	1	 
		  	2.1	  	Delivery of Subscription Notice	  	 	1	 
		  	2.2	  	Conditions Precedent to the Delivery of a Subscription Notice	  	 	1	 
		  	2.3	  	Pricing Period Obligation Limitation and Increase	  	 	3	 
		  	2.4	  	Fee	  	 	3	 
	 3.
	  	Closing Notice	  	 	4	 
	 4.
	  	Subscription for Ordinary Shares	  	 	4	 
		  	4.1	  	Prior Notification of a Subscription Notice	  	 	4	 
		  	4.2	  	Share Provision	  	 	5	 
		  	4.3	  	Further Terms of Share Provision	  	 	5	 
		  	4.4	  	Subscription Closing	  	 	6	 
		  	4.5	  	Issue of Ordinary Shares to the Purchaser or the Share Providers	  	 	7	 
		  	4.6	  	No Claim by Share Providers Against Purchaser	  	 	8	 
		  	4.7	  	Replacement of Share Providers	  	 	8	 
		  	4.8	  	Warranties of the Share Providers	  	 	8	 
	 5.
	  	Representations, Warranties and Undertakings of the Company	  	 	9	 
		  	5.1	  	Representations, Warranties and Undertakings	  	 	9	 
		  	5.2	  	Material Adverse Events	  	 	11	 
		  	5.3	  	Purchasers Reliance	  	 	11	 
	 6.
	  	Representations and Warranties of the Purchaser	  	 	11	 
		  	6.1	  	Organisation; Authority	  	 	12	 
		  	6.2	  	Sale and Purchase of Ordinary Shares	  	 	12	 
		  	6.3	  	Compliance with Swiss Non-Bank Rules	  	 	12	 
	 7.
	  	Other Agreements of the Parties	  	 	13	 
		  	7.1	  	Application of Proceeds	  	 	13	 
	 8.
	  	Termination	  	 	13	 
		  	8.1	  	Termination by Mutual Consent	  	 	13	 
		  	8.2	  	Termination by the Purchaser	  	 	13	 
		  	8.3	  	Effect of Termination	  	 	13	 
	 9.
	  	Miscellaneous	  	 	14	 
		  	9.1	  	Fees and Expenses	  	 	14	 

  
 i 

							
	 9.2
	  	Indemnity	  	 	14	 
	 9.3
	  	Amendments Regarding Swiss Law and Primary Market Regulations	  	 	14	 
	 9.4
	  	Entire Agreement	  	 	14	 
	 9.5
	  	Notices	  	 	15	 
	 9.6
	  	Amendments; Waivers	  	 	15	 
	 9.7
	  	Headings	  	 	15	 
	 9.8
	  	Assignment / Accession to the Agreement as Share Provider	  	 	15	 
	 9.9
	  	No Third-Party Beneficiaries	  	 	16	 
	 9.10
	  	Remedies and Waiver	  	 	16	 
	 9.11
	  	Survival	  	 	16	 
	 9.12
	  	Counterpart Signatures	  	 	16	 
	 9.13
	  	Severability	  	 	16	 
	 9.14
	  	Publicity	  	 	17	 
	 9.15
	  	Withholding and Deductions	  	 	17	 
	 9.16
	  	Further Assurances	  	 	17	 
	 9.17
	  	Cost of Enforcement of this Agreement	  	 	17	 
	 9.18
	  	Acknowledgment by the Company	  	 	18	 
	 9.19
	  	Governing Law and Jurisdiction	  	 	18	 
	 Annex 1 — Definitions
	  	 	20	 
	 Annex 2 — Contact Details of the Purchaser and GEM Management
	  	 	26	 
	 Annex 3 — Details of Share Providers
	  	 	27	 
	 Annex 4 — Form of Subscription Notice
	  	 	28	 
	 Annex 5 — Form of Closing Notice
	  	 	29	 
	 Annex 6 — Form of Assignment and Transfer by the Purchaser
	  	 	30	 
	 Annex 7 — Form of Promissory Note
	  	 	33	 

  
 ii 

 Whereas 

A. The Company has offered GEMYB and the Purchaser the right to subscribe, on the terms and subject to the conditions set out in this
Agreement, for Ordinary Shares in the Company at an aggregate subscription price of up to CHF 50,000,000. 
 B. The Share Providers,
acceding to this Agreement from time to time, wish to provide Ordinary Shares to the Purchaser on the terms set out in this Agreement. 

Now, therefore, the Parties hereto agree as follows: 
  

	1.	 Definitions and References 

 

	 	(a)	 Capitalized terms used in this Agreement have the meanings assigned to them in Annex 1.

  

	 	(b)	 References to clauses and Annexes are, save where the context otherwise requires, to clauses of and Annexes to
this Agreement. 

  

	2.	 Subscription Notice 

 

	2.1	 Delivery of Subscription Notice 

 

	 	(a)	 Subject to the satisfaction (or waiver in writing by the Purchaser) of the conditions set forth in clause 2.2,
on any Trading Day during the Commitment Period, the Company shall be entitled to issue a Subscription Notice to the Purchaser. The Subscription Notice shall be delivered to the Purchaser in accordance with the notice provisions of clause 9.5 and
shall: 

  

	 	(i)	 specify the Draw Down Amount; 

 

	 	(ii)	 specify the Floor Price; and 

 

	 	(iii)	 contain a certificate, signed by a Designated Officer, certifying that all conditions precedent to the delivery
of a Subscription Notice have been satisfied or waived in writing by the Purchaser. 

  

	 	(b)	 Each Subscription Notice shall be irrevocable. The Company may issue as many Subscription Notices as it may
elect during the Commitment Period, but, after delivery of a Subscription Notice, may not, without the prior consent of the Purchaser, thereafter deliver a further Subscription Notice until the expiry of the Pricing Period relating to the
Subscription Notice already delivered. 

  

	2.2	 Conditions Precedent to the Delivery of a Subscription Notice 

The Company may deliver a Subscription Notice only if the following conditions have been and remain satisfied (or waived by the Purchaser in
writing in respect of the relevant Subscription Notice): 
  

	 	(a)	 the Company shall have delivered and the Purchaser shall have received an electronic copy of the executed
Agreement and the executed Promissory Note; 

  
 1 

	 	(b)	 the Provided Shares relating to the relevant Subscription Notice have been delivered to the Purchaser’s
account, to the satisfaction of the Purchaser; 

  

	 	(c)	 the Promissory Note has been duly executed and delivered to GEMYB; 

 

	 	(d)	 the Ordinary Shares remain Listed; 

 

	 	(e)	 the Company has obtained all the Required Approvals (in a form reasonably acceptable to the Purchaser) and such
Required Approvals are in full force and effect such that 200 per cent of the Draw Down Amount (or, if 90 per cent of the Closing Bid Price on the Trading Day on which a Subscription Notice is sent when (i) multiplied by 200 per
cent of the Draw Down Amount and (ii) added to the aggregate Subscription Price of all Ordinary Shares already issued pursuant to Closing Notices would exceed CHF 50,000,000, such smaller percentage of the Draw Down Amount (being not less than
100 per cent) as is capable of being issued without exceeding such CHF 50,000,000 limit) may be duly allotted and issued to the Purchaser; 

  

	 	(f)	 the representations and warranties of the Company contained herein are true and correct in all respects as of
the relevant Notice Date as repeated at that time (except that representations and warranties that are expressed by their terms to be made as of a specific date need be true in all respects only as of such date); 

 

	 	(g)	 the Company and each Share Provider have performed, satisfied and complied in all material respects with all
covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company or the Share Provider (as the case may be) at or prior to the Notice Date; 

 

	 	(h)	 no Material Adverse Event has occurred or is reasonably expected to occur; 

 

	 	(i)	 no inquiry, investigation or other proceeding, whether formal or informal, has been commenced, announced or
threatened, no order has been issued by any governmental or regulatory organisation or stock exchange and there has been no change of law or policy, or the interpretation or administration thereof, in each case which operates or could operate to
prevent, suspend, hinder, delay, restrict or otherwise have a significant adverse effect on the transactions contemplated by this Agreement or which could have a material adverse effect on the Purchaser; and 

 

	 	(j)	 Listing of the issued Ordinary Shares has not been suspended or threatened to be suspended by the Principal
Market during the thirty Trading Days prior to the relevant Notice Date. 

  
 2 

	2.3	 Pricing Period Obligation Limitation and Increase 

On and subject to the terms and conditions of this Agreement, the Purchaser shall be obliged, with respect to any Subscription Notice and
Pricing Period, to subscribe for a number of Ordinary Shares which is not less than 50 per cent of the Pricing Period Obligation, and the Purchaser shall be entitled at its sole discretion to elect to subscribe for up to 200 per cent of
the Pricing Period Obligation, provided that the Purchaser shall not be obliged to subscribe for a percentage of the Pricing Period Obligation that has an aggregate Subscription Price which, when added to the aggregate Subscription Price of all
Ordinary Shares issued pursuant to all prior Closing Notices, would exceed CHF 50,000,000; and further provided in each case that if, on any Trading Day during any Pricing Period, a Material Adverse Event occurs, the Purchaser shall be entitled at
its sole discretion to elect to treat that Trading Day and any other Trading Day during the relevant Pricing Period as a Knockout Day. The Purchaser shall not be obliged to purchase any Ordinary Shares pursuant to this Agreement (i) if the
Purchaser would in consequence be required to make a mandatory tender offer to purchase all or any of the outstanding Ordinary Shares or (ii) if as of the Closing Date the Company has not obtained all of the Required Approvals. 

 

	2.4	 Fee 

  

	 	(a)	 The Company shall pay to GEMYB a fee of CHF 1,250,000 (which sum shall be deemed to be exclusive of any
applicable taxes and duties) (the Fee), payable out of the proceeds resulting from Subscription Prices paid by the Purchaser, as further specified in this clause 2.4. The Company shall, on the date of this Agreement, provide a Promissory Note as
evidence of its obligation to pay the Fee. 

  

	 	(b)	 The Purchaser shall deduct from the sum payable by it in respect of the aggregate Subscription Price payable by
it pursuant to a Closing Notice on a Closing Date the amount of the Fee or, if less, the portion thereof equal to such aggregate Subscription Price and shall pay such amount to GEMYB on behalf of the Company. Such deduction shall be a full discharge
to the Company of its obligation to pay the Fee or the relevant portion thereof (as the case may be). 

  

	 	(c)	 If on the expiry of twelve (12) months from the date of this Agreement no Closing Date has occurred, the
Company shall pay the total outstanding amount of the Fee to GEMYB. 

  

	 	(d)	 It is therefore expressly acknowledged that the Fee shall be due on the first anniversary of the Agreement,
regardless of whether a Closing Date has occurred before that date. 

  

	 	(e)	 It is hereby acknowledged that if, on any date prior to the Payment Date (as that term is defined in the
Promissory Note) the Company pays any portion of the Fee (the Paid Amount) to GEMYB the amount due to GEMYB under the Promissory Note shall be reduced by an amount equal to the Paid Amount. In such circumstances, the Company shall issue a new
Promissory Note to GEMYB for an amount equal to the Fee minus the Paid Amount (or if a number of payments have been made, the aggregate of all such Paid Amounts) against surrender by GEMYB of its existing Promissory Note to the Company.

  
 3 

	 	(f)	 If for any reason: 

  

	 	(i)	 the Company fails to comply with its obligations to pay the Fee or any portion thereof in accordance with any
of the provisions of this clause 2.4; 

  

	 	(ii)	 the Company or any Share Provider has breached in any material respect any representation, warranty, covenant
or agreement contained in this Agreement and (if such breach is curable) such breach is not cured within five Business Days following receipt by the Company of notice of such breach or there has been any Material Adverse Event;

  

	 	(iii)	 the Company ceases to carry on business at any time before the Fee is paid in full; or 

 

	 	(iv)	 any steps are taken by any person to initiate any form of insolvency, composition or administration proceedings
in relation to the Company before the Fee is paid in full; 

 the outstanding balance of the Fee at that time shall become
immediately due and payable. 
  

	 	(g)	 If any sum payable under this clause 2.4 is not paid on the due date of payment, interest shall accrue on such
sum from and including the due date for payment to but excluding the date on which payment is made at a rate of one hundred (100) basis points per annum (calculated on a 30/365 basis) above the base rate of Barclays Bank PLC from time to
time, compounded monthly. If the applicable base rate is less than zero, the applicable base rate shall be deemed zero. 

  

	3.	 Closing Notice 

At or before 9.00 a.m. (Swiss time) on the first Trading Day immediately following the end of each Pricing Period, the Purchaser shall deliver
to the Company a Closing Notice stating the exact number of Ordinary Shares for which it wishes to subscribe in accordance with clause 2.3 stating the applicable Subscription Price and attaching copy extracts from Bloomberg showing each of the
Closing Bid Prices during the Pricing Period. 
  

	4.	 Subscription for Ordinary Shares 

 

	4.1	 Prior Notification of a Subscription Notice 

Unless otherwise agreed, not later than five (5) Trading Days prior to the delivery of a Subscription Notice, the Company shall notify
each of the Share Providers and the Purchaser in writing of its intention to deliver a Subscription Notice on a Notice Date and shall specify in such notification the Draw Down Amount and the Notice Date. For the avoidance of doubt the Company shall
not be obliged to proceed to issue a Subscription Notice following such notification but in the event that it decides not to do so it shall notify the Share Providers and the Purchaser thereof promptly in writing. 

  
 4 

	4.2	 Share Provision 

 

	 	(a)	 The Share Providers shall be deemed upon receipt of any such notification to offer (the Offer) and shall be
obliged to provide, as a lender, Ordinary Shares to the Purchaser on the following terms: 

  

	 	(i)	 the total number of Ordinary Shares which the Share Providers shall offer to provide (excluding any Ordinary
Shares which have already been provided and which have not yet been returned to the relevant Share Provider by the Purchaser pursuant to this Agreement) (the Provided Shares) shall be equal to 200 per cent of the Draw Down Amount;

  

	 	(ii)	 the Purchaser shall be deemed to accept the Offer in full unless it shall have notified the Share Providers
otherwise on or prior to the date which is four (4) Trading Days prior to the Notice Date; 

  

	 	(iii)	 the Share Providers shall together deliver the Provided Shares which are to be delivered (the Share Provision)
to the Settlement System account of the Purchaser prior to the Notice Date; and 

  

	 	(iv)	 the Settlement System account to be used for each delivery of Provided Shares shall be designated by the
Purchaser not later than three (3) Trading Days prior to the relevant Notice Date, such designation being binding with respect to all future deliveries of Provided Shares unless the Share Providers are informed by the Purchaser in writing of
the details of a new account to be used for deliveries of Provided Shares on a Notice Date on or prior to the date which is three (3) Trading Days prior to such Notice Date. 

 

	 	(b)	 In the event that the Company does not proceed to issue a Subscription Notice following the making of a
notification of an intention to do so under clause 4.1 on the Notice Date specified in the notification from the Company under clause 4.1 or within a period of three (3) Trading Days thereafter, the Offer made by the Share Providers in relation
thereto and any contract with the Purchaser in respect of Provided Shares relating thereto shall be deemed to be terminated with immediate effect and the Purchaser shall, at the cost of the Share Providers, procure that any Provided Shares which
have been delivered to the Purchaser’s Settlement System account pursuant to such Offer shall be promptly returned to the relevant Share Providers. 

  

	4.3	 Further Terms of Share Provision 

 

	 	(a)	 Each Share Provision shall be concluded for a term commencing on the date of delivery of the Provided Shares to
the Purchaser and, subject to clause 4.6, ending on the day on which the Purchaser shall have discharged its obligations in respect thereof under this clause 4.3. 

 

	 	(b)	 The number of Ordinary Shares to be subscribed by the Purchaser on a Closing Date shall be referred to as the
Issue Amount. Where the number of Provided Shares transferred to the Purchaser by the Share Providers in connection with a Subscription Notice is greater than the Issue Amount specified in the corresponding Closing Notice, the Purchaser shall return
to the Share Provider any Provided Shares received in excess of the Issue Amount without undue delay, but in any case by no later than the first Business Day on which the Settlement System is in operation following the Closing Date.

  
 5 

	 	(c)	 After the Ordinary Shares issued pursuant to this Agreement have been Listed, the Purchaser shall repay the
balance of the relevant Share Provision by either transferring a number of Ordinary Shares which is equal to the number of outstanding Provided Shares to the Share Providers or giving instructions for such repayment to be effected by direct issue of
that number of Ordinary Shares to the Share Providers in accordance with clause 4.5. The Purchaser discharges all its obligations to the Share Providers in respect of the delivery of such number of Ordinary Shares to the Share Providers by giving
such instructions in accordance with clause 4.5. If the Purchaser performs its obligations to pay the money due under clause 4.4(b)(i) in respect of the Ordinary Shares to be subscribed pursuant to any Closing Notice, it shall have no liability or
responsibility to the Share Providers if the Company fails to comply with its obligation in respect of the issue or delivery of the relevant Ordinary Shares and in such event the Purchaser shall discharge all its obligations to the Share Providers
under this clause 1.2(c)(c) by assigning to the Share Providers its rights to receive from the Company the relevant number of Ordinary Shares. 

  

	 	(d)	 Where there is at any time more than one Share Provider, their obligations under this Agreement are undertaken
by them jointly and severally and the Share Providers shall be responsible for informing the Purchaser to which of them any Ordinary Shares are to be transferred or rights to receive Ordinary Shares are to be assigned in accordance with clause
1.2(c) and any Provided Shares are to be returned to in accordance with clause 4.2 or clause 1.2(b). 

  

	4.4	 Subscription Closing 

 

	 	(a)	 Subject to: 

  

	 	(i)	 the satisfaction (or waiver in writing by the Purchaser) of the conditions set out in clause 2.2 as at the
Closing Date (but so that all references in such conditions to “the Notice Date” shall for the purposes of this clause 4.4 be treated as referring to “the Closing Date”); 

 

	 	(ii)	 the subscription and payment for the Ordinary Shares pursuant to the relevant Closing Notice and Listing of
such Ordinary Shares not being prohibited or enjoined (temporarily or permanently) by any applicable law or governmental or other regulation including the Listing Rules (other than by reason of the Purchaser’s breach of its representations,
warranties and/or undertakings in this Agreement); and 

  

	 	(iii)	 no change having become effective between the date of this Agreement and each Closing Date, in any law or
regulation (whether governmental or otherwise) which would adversely affect in any material aspect the holding or disposal of Ordinary Shares by the Purchaser or the Purchaser’s rights in respect thereof: 

  
 6 

	 	(b)	 on the first Trading Day following the applicable Pricing Period or, if the Settlement System is not in
operation on that day, the next Trading Day on which the Settlement System is in operation (each, a Closing Date): 

  

	 	(i)	 the Purchaser shall apply to the Company to subscribe for the number of Ordinary Shares set out in the relevant
Closing Notice and shall remit by wire transfer to an account or to accounts designated by the Company an amount equal to the product of (A) such number of Ordinary Shares and (B) the applicable Subscription Price; the
Parties acknowledge and agree that this payment will be made as an advance payment by the Purchaser of the aggregate Subscription Price for the Ordinary Shares to be issued pursuant to the relevant Closing Notice and the Company will apply the
relevant sum in full (without deduction) towards the fulfilment of the Purchaser’s obligation to pay the Subscription Price applicable to the Ordinary Shares; and 

 

	 	(ii)	 the Company shall acknowledge in writing to the Purchaser that it has received an application from the
Purchaser to subscribe for the relevant number of Ordinary Shares and an amount equal to the aggregate Subscription Price for such Ordinary Shares, and shall send a copy of such acknowledgment to the Share Providers. 

 

	4.5	 Issue of Ordinary Shares to the Purchaser or the Share Providers 

Within twelve (12) months of any Closing Date the Company shall issue or deliver to the Purchaser the number of Ordinary Shares subscribed
for by the Purchaser on the relevant Closing Date. This issue or delivery shall be made, at the Purchaser’s option, either by way of crediting such aggregate number of Listed Ordinary Shares to the Purchaser’s Brokerage Account specified
in the Closing Notice (provided that an account with the account number set forth in the Closing Notice has been opened and remains open) or by crediting them to another account or accounts designated by the Purchaser. The Purchaser may, as provided
in clause 4.3(c), instruct the Company to book such Ordinary Shares in a freely tradable and Listed form on its behalf to an account or accounts designated by the Share Providers as are required to be booked to the Share Providers in fulfilment of
its obligation to repay the equivalent number of Ordinary Shares to the Share Providers under the relevant Share Provision. The Purchaser may revoke the foregoing instruction to the Company if the Share Providers are in breach of any material term
of this Agreement. The Company hereby undertakes to the Share Providers and the Purchaser that it shall comply with all instructions from the Purchaser given pursuant to this clause 4.5. To the extent required under applicable Swiss corporate law,
the Purchaser or the Share Provider(s) shall execute a subscription form in accordance with Article 652 para. 1 and 2 in connection with Article 630 no. 2 of the Swiss Code of Obligations. 

  
 7 

	4.6	 No Claim by Share Providers Against Purchaser 

The Share Providers shall have no claim against the Purchaser in respect of any failure to deliver to them a number of Ordinary Shares equal to
the number of Provided Shares if and to the extent that (i) the Purchaser has subscribed for the number of Ordinary Shares set out in the relevant Closing Notice, and (ii) the Purchaser has instructed the Company to deliver a number of
Ordinary Shares equal to the number of Provided Shares which remain outstanding pursuant to the relevant Share Provision to the Share Providers. 
  

	4.7	 Replacement of Share Providers 

A Share Provider may withdraw from this Agreement subject to notifying the Company and the Purchaser of its intention thereof and subject to a
notice period of three (3) months. The Purchaser shall thereafter not have any obligations under this Agreement until one or more persons has executed a deed of adherence in which they confirm that they have become a party to this Agreement in
the capacity of a Share Provider and agree to be bound by all applicable terms of this Agreement. 
  

	4.8	 Warranties of the Share Providers 

The warranties in this clause 4.8 shall be deemed to have been repeated as at each Notice Date, as at each Closing Date and as at each date on
which Ordinary Shares are issued or delivered to the Purchaser’s Settlement System account pursuant to this Agreement with reference to the facts and circumstances existing on that date. Each Share Provider hereby represents, warrants and
undertakes to the Purchaser that the following statements are true and accurate in all respects: 
  

	 	(a)	 such Share Provider has the requisite power and authority to enter into and to consummate the transactions
contemplated hereby and otherwise to carry out its obligations hereunder; 

  

	 	(b)	 such Share Provider is the legal and beneficial owner of any Provided Shares it provides pursuant to this
Agreement; and 

  

	 	(c)	 such Share Provider is not required to obtain any consent, waiver, authorization or order of, or make any
filing (other than making the necessary disclosures pursuant to the Swiss Financial Markets Infrastructure Act and its implementing ordinances and regulations) or registration with, any court or other governmental or regulatory authority or other
Person (including the approval of its director) in connection with the execution, delivery and performance by it of this Agreement and as of the Notice Date and as of the Closing Date any necessary consents and approvals have been obtained and
remain in full force in respect of the provision of the Provided Shares. 

  
 8 

	5.	 Representations, Warranties and Undertakings of the Company 

 

	5.1	 Representations, Warranties and Undertakings 

The Company hereby represents, warrants and undertakes to the Purchaser that the Warranties are true and accurate in all respects as at the
date of this Agreement. The Warranties shall be deemed to have been repeated as at each Notice Date, as at each Closing Date and as at each date on which Ordinary Shares become issued and Listed pursuant to this Agreement with reference to the facts
and circumstances existing on that date. 
  

	 	(a)	 Organisation and Qualification 

Each of the Company and each of its Subsidiaries is duly incorporated and validly existing under the laws of its country of incorporation with
the requisite corporate power and authority to own and use its properties and assets and to carry on its business as currently conducted. 
  

	 	(b)	 Organisation of Share Capital 

The Ordinary Shares are and, for so long as this Agreement remains in force, will remain the only class of shares in the equity share capital
of the Company (where “equity share capital” refers to the issued shares of capital stock of the Company excluding any class of shares which neither as respects dividends nor as respects capital carry any right to participate beyond a
specified amount in the distribution) and the Company shall not for so long as this Agreement remains in force issue any shares which have rights differing from those attaching to the equity share capital in issue as at the date of this Agreement.

  

	 	(c)	 Authorization; Enforcement 

 

	 	(i)	 The Company has the requisite corporate power and authority to enter into this Agreement and on each Closing
Date, to consummate the transactions contemplated by this Agreement that are to be consummated on that Closing Date and otherwise to carry out its obligations under this Agreement. 

 

	 	(ii)	 The execution and delivery of this Agreement and the completion by it of the transactions required hereby have
been duly authorized by all necessary action on the part of the Company, its directors and its shareholders. 

  

	 	(iii)	 This Agreement has been duly executed and delivered by the Company or on its behalf and the obligations assumed
by the Company under this Agreement constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms. 

  

	 	(d)	 Share Capital 

As at the Notice Date, the issue of Ordinary Shares which may be issued as a result of the relevant Subscription Notice will not be subject to
any pre-emptive or similar rights. 

  
 9 

	 	(e)	 Issue of Ordinary Shares 

The Company has at the Notice Date, and thereafter during each Pricing Period immediately prior to the corresponding Closing Date, an adequate
authorized and/or conditional share capital allowing it to issue Ordinary Shares, and/or holds a sufficient number of Ordinary Shares in treasury, to enable it to allot and issue or deliver the number of Ordinary Shares equal to 200 per cent of
the Draw Down Amount set forth in the relevant Subscription Notice. The Ordinary Shares shall be free of any Liens, duly authorized, validly issued, fully paid and freely tradable, and application shall be made forthwith for the Ordinary Shares to
be Listed. 
  

	 	(f)	 No Conflicts 

The execution, delivery and performance of this Agreement and the issue of Ordinary Shares by the Company pursuant to this Agreement, and the
completion by the Company, as applicable, of the transactions contemplated hereby, do not and will not conflict with or violate any provision of the Articles. 
  

	 	(g)	 Consents and Approvals 

Except for any necessary approvals from the Principal Market for the Listing of Ordinary Shares issued pursuant to a Subscription Notice, the
internal approvals referred to in clause 5.1(c)(ii), disclosures pursuant to the Swiss Financial Markets Infrastructure Act and its implementing ordinances and regulations, the registration of any newly issued Ordinary Shares with the commercial
register, neither the Company nor any Subsidiary is required to obtain any consent, waiver, authorization or order of, or make any filing or registration with, any court or other governmental or regulatory authority or other Person in connection
with the execution, delivery and performance by the Company of this Agreement and the issue of Ordinary Shares pursuant to a Closing Notice. As of the Closing Date any necessary consents and approvals (including, for the avoidance of doubt, any
necessary approvals as referred to above from the Principal Market) in respect of any Ordinary Shares required to be issued pursuant to any Subscription Notice served by the Company (collectively, the Required Approvals) have been obtained and are
in full force and effect. The Company shall procure that all Provided Shares are Listed at all times, that all Ordinary Shares issued pursuant to this Agreement shall, subject to the Listing of the Ordinary Shares already in issue remaining
effective, be Listed with effect from opening of business on the Trading Day immediately following their issue date. 
  

	 	(h)	 Litigation; Proceedings 

There is no action, suit, notice of violation, proceeding or investigation pending or, to the best knowledge of the Directors of the Company,
threatened against the Company or any of its Subsidiaries or any of their respective properties or assets before or by any court, governmental or administrative agency or regulatory authority which (i) relates to or challenges the legality,
validity or enforceability of this Agreement or (ii) could, individually or in the aggregate, be reasonably expected to impair materially the ability of the Company or the Share Providers to perform fully on a timely basis its obligations under
this Agreement. 

  
 10 

	 	(i)	 Exchange/Market 

The Ordinary Shares in issue are Listed. After consultation prior to each Notice Date with the Company’s relevant advisers and brokers,
the Company knows of no reason why the Principal Market will not admit to Listing the maximum number of Ordinary Shares which may be issued pursuant to this Agreement. 
  

	 	(j)	 Non-Public Information 

The Company acknowledges that neither it nor any of its representatives or agents has provided the Purchaser or any of its representatives or
agents identified to or known by the Company as such with what it reasonably believes to be any material non-public information regarding or related to the Company or its respective operations, personnel,
technologies or prospects that has not otherwise been made publicly available. 
  

	 	(k)	 Solvency 

The Company and its Subsidiaries are Solvent. No transfer of property has been or is being made by the Company or its Subsidiaries and no
obligation has been or is being incurred by the Company or its Subsidiaries in connection with the transactions contemplated by this Agreement or related documents with the intent to hinder, delay or defraud creditors of the Company or any
Subsidiary. 
  

	5.2	 Material Adverse Events 

The Company hereby agrees that as at each Closing Date and as at each date on which Ordinary Shares are to be issued pursuant to this Agreement
it shall be deemed to represent and warrant to the Purchaser that there shall have been no Material Adverse Event which occurred or became public or generally known since the immediately preceding Notice Date (in relation to Ordinary Shares to be
issued pursuant to this Agreement) or which is reasonably expected to occur. 
  

	5.3	 Purchasers Reliance 

The Company acknowledges that the Purchaser is entering into this Agreement and will subscribe for Ordinary Shares pursuant to this Agreement
in reliance on the representations, warranties, undertakings and covenants of the Company contained in this Agreement, including those contained in clauses 5.1 and 5.2. 
  

	6.	 Representations and Warranties of the Purchaser 

The Purchaser hereby represents, warrants and undertakes to the Company that the following statements are true and accurate in all respects.
The warranties are deemed to be repeated on each Notice Date, each Closing Date and each date on which Ordinary Shares become issued pursuant to the Agreement with reference to the facts and circumstances existing at that date. 

  
 11 

	6.1	 Organisation; Authority 

The Purchaser is a company duly formed and validly existing under the laws of Luxembourg. The Purchaser has the requisite power and authority
to enter into and to consummate the transactions contemplated hereby and otherwise to carry out its obligations hereunder. The subscription of the Ordinary Shares pursuant to this Agreement by the Purchaser have been duly authorized by all necessary
action on part of the Purchaser, its directors and shareholders. This Agreement has been duly executed and delivered by the Purchaser or on its behalf and the obligations assumed by the Purchaser pursuant to this Agreement constitute valid and
legally binding obligations of the Purchaser, enforceable against the Purchaser. 
  

	6.2	 Sale and Purchase of Ordinary Shares 

 

	 	(a)	 The Purchaser agrees that it shall not at any time during the Commitment Period sell Ordinary Shares exceeding
the number of Ordinary Shares which it owns and/or has the right to subscribe for pursuant to an outstanding Subscription Notice. For the avoidance of doubt, during each Pricing Period the Purchaser shall have the right to sell an amount of Ordinary
Shares equal to up to 200% of the Draw Down Amount stated in the relevant Subscription Notice. 

  

	 	(b)	 The Purchaser undertakes that, during a Pricing Period, it shall not on any Trading Day sell Ordinary Shares
exceeding such number as represent one 15th of 200% of the Draw Down Amount specified in the relevant Subscription Notice. 

  

	6.3	 Compliance with Swiss Non-Bank Rules 

 

	 	(a)	 The Company shall ensure that it is at all times in compliance with the
Non-Bank Rules. 

  

	 	(b)	 With respect to any deduction on account of Swiss Withholding Tax, clause 6.3(a) above shall not be breached if
the number of creditors of the Company in respect of either the 10 Non-Bank Rule or the 20 Non-Bank Rule is exceeded solely as a result of a failure by the Purchaser to
comply with its obligations under clause 9.8(b), the Purchaser having given an incorrect information as to its status as Qualifying Bank or having lost its status as Qualifying Bank or as one (1) creditor only for the purposes of the Non-Bank Rules. For the avoidance of doubt, the Company acknowledges that it is aware of the fact that the Purchaser does not qualify as Qualifying Bank but counts as one (1) creditor for the purposes of the Non-Bank Rules. 

  
 12 

	7.	 Other Agreements of the Parties 

 

	7.1	 Application of Proceeds 

The Company covenants and undertakes with the Purchaser and GEMYB that it shall procure that the subscription monies received by the Company
pursuant to this Agreement shall be used by the Company and its subsidiaries primarily for general corporate purposes and for working capital purposes. 
  

	7.2	 Solicitation Materials 

Other than as may be required by law or any regulation, the Company, its Affiliates and any Person acting on their behalf have not and shall
not: (i) distribute any offering materials in connection with the offering and issue of Ordinary Shares pursuant to this Agreement, except as required under the Listing Rules; (ii) solicit any offer to buy or sell such securities by means
of any form of general solicitation or advertising; (iii) engage in any “directed selling efforts” as such term is defined in Rule 902 under the Securities Act; or (iv) take any action which would subject the issue of such
Ordinary Shares to the registration requirements of section 5 of the Securities Act or to any securities laws of any applicable jurisdiction. 
  

	8.	 Termination 

  

	8.1	 Termination by Mutual Consent 

This Agreement may be terminated at any time during the Commitment Period by the mutual consent of the Company, the Purchaser and GEMYB. 

 

	8.2	 Termination by the Purchaser 

This Agreement may be terminated forthwith during the Commitment Period by the Purchaser by giving written notice of such termination to the
Company if: (a) the Company or any Share Provider has breached in any material respect any representation, warranty, covenant or agreement contained in this Agreement (including any failure to issue and/or, procure the Listing of Ordinary
Shares on time) and (if such breach is curable) such breach is not cured within five (5) Business Days following receipt by the Company of notice of such breach; (b) there has been a change in applicable law which materially impacts the
Purchaser’s obligations under this Agreement; or (c) there has been any Material Adverse Event; or (d) there has been a Material Change in Ownership. 
  

	8.3	 Effect of Termination 

In the event of the termination of this Agreement pursuant to this clause 8 the Parties shall retain all accrued rights and shall retain all
rights and remain bound by all obligations under this Agreement as respects Ordinary Shares previously issued to the Purchaser (or its nominee(s)) hereunder, and nothing herein shall relieve any terminating Party from liability for any prior breach
of any of its agreements, covenants, representations, warranties or other obligations under this Agreement or for fraud. 

  
 13 

	9.	 Miscellaneous 

 

	9.1	 Fees and Expenses 

 

	 	(a)	 The Company shall pay all and any stamp duty or share transfer or registration or similar duties, taxes or fees
arising under the laws of any jurisdiction in connection with the subscription by the Purchaser (or its nominee(s)) for Ordinary Shares pursuant to this Agreement and each other transaction pursuant to this Agreement. 

 

	 	(b)	 Other than as expressly set out in this Agreement, each of the Company, the Purchaser and GEMYB shall pay its
own costs, fees and expenses in connection with the negotiation and execution of this Agreement and the completion of the transactions contemplated by this Agreement. 

 

	9.2	 Indemnity 

In addition to all of the Company’s other obligations under this Agreement, the Company shall defend, protect, indemnify and hold harmless
the Purchaser, GEMYB and any assignee of their rights under this Agreement and their respective directors, partners, members, shareholders, managers, officers, employees and agents (collectively, the Indemnified Persons) from and against any and all
actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of whether any such Indemnified Person is a party to the action for which indemnification hereunder
is sought), and including reasonable attorneys’ fees and disbursements (the Indemnified Liabilities) incurred by any Indemnified Person as a result of, arising out of, or relating to (a) any misrepresentation or breach of any
representation or warranty made by the Company in this Agreement or any other certificate, instrument or document contemplated hereby, (b) any breach of any covenant, agreement or obligation of the Company contained in this Agreement or any
other certificate, instrument or document contemplated thereby, and (c) any proceeding, investigation, cause of action, suit or claim brought, made or threatened against such Indemnified Person as a result of, arising out of, or relating to
(i) the execution, delivery, performance or enforcement of this Agreement or any other certificate, instrument or document contemplated hereby or (ii) the Indemnified Person being an investor in the Company. To the extent that the
foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law. 

 

	9.3	 Amendments Regarding Swiss Law and Primary Market Regulations 

To the extent required or practical due to the requirements under Swiss law and the Primary Market regulations, the Parties shall amend this
Agreement as necessary or practicable to comply with Swiss law and/or the Primary Market regulations, in particular with regard to the mechanics of the issuance, deliver and Listing of the Ordinary Shares. 

 

	9.4	 Entire Agreement 

This Agreement (including the Annexes to it) contains the entire agreement and understanding of the Parties with respect to the subject matter
of this Agreement and supersedes all prior agreements and understandings, oral or written, relating to the subject matter of this Agreement. For the avoidance of doubt, all letters and any other arrangements between the Company, the Purchaser and
GEMYB written or entered into prior to the date of this Agreement shall cease to be of any effect and no party shall have any claim or right of action pursuant thereto. 

  
 14 

	9.5	 Notices 

Any notice or other communication required or permitted to be given under the terms of this Agreement shall be in writing and shall be deemed
to have been received upon hand delivery (receipt acknowledged), facsimile transmission (with transmission confirmation report) (if a fax number has been provided for such purposes) or email (if an email address has been provided for such purposes)
to the address or number designated below (if delivered on a Business Day prior to 5:00 p.m., Swiss time), or on the first Business Day following such delivery (if delivered other than prior to 5:00 p.m., Swiss time on a Business Day). The addresses
and numbers for such communications shall be: for the Purchaser and GEMYB, as specified in Annex 2; for the Share Providers, as specified in Annex 3; and for the Company, its registered office for the time being and email address
jeremy.meinen@relieftherapeutics.com, in all cases, such other address and fax number as shall be notified in writing by the recipient party to the sending party from time to time. 

 

	9.6	 Amendments; Waivers 

No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment, by each of the
Company and the Purchaser, or, in the case of a waiver, by the Party against whom enforcement of any such waiver is sought. 
  

	9.7	 Headings 

The headings in this Agreement are for convenience only, and shall be ignored in construing its terms. 

 

	9.8	 Assignment / Accession to the Agreement as Share Provider 

 

	 	(a)	 The Company may not assign or otherwise transfer any of its rights under this Agreement. 

 

	 	(b)	 The Purchaser shall be entitled to assign its rights and obligations (in whole or in part) under this Agreement
to any Affiliate of the Purchaser or GEMYB, but not to any other Person. Any permitted assignment of the Purchaser’s rights or obligations shall be effected by the entry by the Purchaser and the assignee into a assignment and transfer in the
form set out in Annex 6 (into which the Company shall promptly enter on the request of the Purchaser). 

  

	 	(c)	 Any Person intending to enter into this Agreement as a Share Provider after the date of this Agreement must do
so in writing, confirming that it acknowledges all of the contractual obligations relating thereto. Such Person shall be deemed to be a Share Provider under the Agreement upon the written consent of all Parties to such Person’s entry into the
Agreement. 

  
 15 

	9.9	 No Third-Party Beneficiaries 

A person who is not a party to this Agreement (other than a permitted transferee or assignee to whom rights have been transferred in accordance
with clause 9.8) has no rights under Article 112 of the Swiss Code of Obligations (or under equivalent legislation in any jurisdiction) to enforce any term of this Agreement but this does not affect any right or remedy of a third party which exists
or is available apart from that provision. 
  

	9.10	 Remedies and Waiver 

The remedies provided in this Agreement shall be cumulative and in addition to all other remedies available under this Agreement or otherwise
provided by law. Any delay by either party in exercising or failing to exercise any right or remedy under this Agreement shall not constitute a waiver of the right or remedy or a waiver of any other rights or remedies and no single or partial
exercise of any rights or remedy under this Agreement or otherwise shall prevent any further exercise of the right or remedy or the exercise of any other right or remedy. Any waiver of a breach of any of the terms of this Agreement or of any default
hereunder shall not be deemed to be a waiver of any subsequent breach or default and shall in no way affect the other terms of this Agreement. 
  

	9.11	 Survival 

The representations, warranties, covenants and agreements of the Company, the Share Providers and the Purchaser contained in this Agreement
shall survive the signing of this Agreement, each Notice Date, each Closing Date, the termination of the Commitment Period and the termination of this Agreement to the extent provided in clause 8.3. 

 

	9.12	 Counterpart Signatures 

This Agreement may be executed and delivered by each Party in separate counterparts, each of which when so executed and delivered shall be
deemed an original and all of which taken together shall constitute one and the same Agreement. This Agreement and any other transaction document relating to this Agreement, and any amendments hereto or thereto, to the extent signed and delivered by
means of a facsimile machine, electronic signature or e-signature (irrespective of whether the relevant electronic signature or e-signature has been issued by a provider
recognized or accredited under applicable law or not) or other electronic transmission (e.g., email delivery in .pdf format or similar format), shall be treated in all manner and respects as an original contract and shall be considered to
have the same binding legal effects as if it were the original signed version thereof delivered in person. 
  

	9.13	 Severability 

In case any one or more of the provisions of this Agreement shall be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby. 

  
 16 

	9.14	 Publicity 

The Company covenants to the Purchaser that: (a) immediately upon execution of this Agreement, it shall make a public announcement, in
terms agreed with the Purchaser and in accordance with the requirements of the Principal Market, of the fact that this Agreement has been entered into by the Company; and (b) in the event that a Subscription Notice or a Closing Notice is issued
and the fact of such issue can reasonably be expected to constitute inside information within the meaning of the Swiss Financial Markets Infrastructure Act and its implementing ordinances and regulations or any other relevant legislation concerning
the use of inside information in relation to listed securities, it shall forthwith upon such issue announce details thereof in accordance, where applicable, with the requirements of the Principal Market. Save to the extent required by law or by the
Principal Market or any other regulatory authority (in which case the Company and the Purchaser shall be obligated to use their respective reasonable endeavours to consult with one another), the Company and the Purchaser shall have the right to
approve before issue any press releases or any other public statement which the other may propose to issue or make with respect to any aspect of the transactions contemplated hereby (other than any announcement required pursuant to part (b) of
the first sentence of this clause 9.14). 
  

	9.15	 Withholding and Deductions 

All payments and transfers to be made by the Company pursuant to this Agreement or any document entered into pursuant to it shall be made
without set-off or counterclaim and free and clear of and without deduction or withholding for or on account of any tax except to the extent, if any, required by any applicable law. If the Company is required
to make any deduction or withholding from any sum payable or transfer to be made by the Company to the Purchaser or GEMYB, the Company shall pay an additional amount or make an additional transfer to the Purchaser or GEMYB so as to ensure that,
after the making of the deduction or withholding, the Purchaser or GEMYB (as the case may be) receives and retains (free from any liability in respect of any such deduction or withholding) a net payment or transfer equal to that which it would have
received and so retained had no such deduction or withholding been made. 
  

	9.16	 Further Assurances 

Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such
other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the completion of the transactions contemplated hereby. 

 

	9.17	 Cost of Enforcement of this Agreement 

In the event that either the Purchaser or GEMYB takes any action to enforce any of the terms of, or preserve any rights under, this Agreement
or to recover any sum owed to it in accordance with this Agreement, the Company shall forthwith on demand reimburse the Purchaser and/or GEMYB and/or any of their Affiliates, as the case may be, for all costs and expenses (including legal fees and
applicable taxes) reasonably incurred in connection with such enforcement. 

  
 17 

	9.18	 Acknowledgment by the Company 

The Company hereby acknowledges that: 
  

	 	(a)	 it has read and understood fully the content of this Agreement, including, but not limited to, the pricing
mechanisms, the Knockout Days, the number of Ordinary Shares to be subscribed for at the end of each Pricing Period, the payment of the Fee and that it is entering into this Agreement on the basis of its own independent assessment of the risks and
liabilities undertaken hereunder, without any representation having been made by the Purchaser or GEMYB or any of their Affiliates as to the effect, operation or results of this Agreement; and 

 

	 	(b)	 it has been advised by its own legal and financial advisers in relation to its assessment of the risks and
liabilities undertaken hereunder and that neither the Purchaser nor GEMYB nor any of their Affiliates has provided investment advice to the Company in connection with the matters agreed in this Agreement or has solicited or induced the Company to
enter into this Agreement. 

  

	9.19	 Governing Law and Jurisdiction 

 

	 	(a)	 This Agreement (together with all documents to be entered into pursuant to it which are not expressed to be
governed by another law) and any dispute or claim arising out of or in connection with it or its subject matter existence, validity or termination (including non-contractual disputes or claims) is governed by
and shall be construed and take effect in accordance with the laws of Switzerland without giving effect to any choice of law or conflict of law provision or rule that would cause the application of the laws of any jurisdiction other than
Switzerland. 

  

	 	(b)	 Any dispute, controversy or claim arising out of, in connection with or relating to this Agreement (or
subsequent amendments thereof), including without limitation, disputes, controversies or claims regarding its existence, validity, invalidity, breach or termination, shall be finally resolved by arbitration in accordance with the Swiss Rules of
International Arbitration of the Swiss Chambers’ Arbitration Institution in force on the date on which the Notice of Arbitration (as such term is defined in the Swiss Rules of International Arbitration of the Swiss Chambers’ Arbitration
Institution) is submitted in accordance with such rules. The number of arbitrators shall be one. The seat of the arbitration shall be Zurich. The arbitral proceedings shall be conducted in English. 

[signatures on next page] 

  
 18 

 Executed as of the date written on the cover page to this Agreement 

RELIEF THERAPEUTICS Holding SA 
  

	
	/s/ Thomaz Burckhardt
	Name: Thomaz Burckhardt
	Function: Director

  

	
	GEM Global Yield LLC SCS
	
	/s/ Christopher F. Brown
	Name: Christopher F. Brown
	Function: Manager

  

	
	GEM Yield Bahamas Ltd
	
	/s/ Christopher F. Brown
	Name: Christopher F. Brown
	Function: Director

  
 19 

 Annex 1 — Definitions 

The following terms used in this Agreement shall, unless the context otherwise requires, bear the following meanings: 

 

			
	10 Non-Bank Rule	  	means the rule that the aggregate number of creditors under this Agreement which are not Qualifying Banks must not at any time exceed ten (10), if and as long as a violation of this rule results in Swiss Withholding Tax consequences
for the Company, in each case in accordance with the meaning of the Guidelines or the applicable legislation or explanatory notes addressing the same issues that are in force at such time;
		
	20 Non-Bank Rule	  	means the rule that (without duplication) the aggregate number of lenders (including the Purchaser) other than Qualifying Banks, of the Company under all its outstanding debts relevant for classification as debenture
(Kasse-nobligation) must not at any time exceed twenty (20), if and as long as a violation of this rule results in Swiss Withholding Tax consequences for the Company, in each case in accordance with the meaning of the Guidelines or the applicable
legislation or explanatory notes addressing the same issues that are in force at such time;
		
	Affiliate	  	with respect to any Person, any other Person that gives or receives non-binding investment directions or recommendations to or from such Person or any other Person that, directly or
indirectly, controls, is controlled by or is under common control with such Person, and for the purpose of this definition, “control” (including, with correlative meanings, the terms “controlled by” and “under common control
with”) shall be interpreted in accordance with Article 963 of the Swiss Code of Obligations;
		
	Agreement	  	means this Share Subscription Facility Agreement;
		
	Articles	  	the Articles of Association (or equivalent constitutional documents) of the Company (as amended from time to time);
		
	Bloomberg	  	Bloomberg Financial Markets;

  
 20 

			
	Business Day	  	any day (except any Saturday or Sunday) on which banks in the city of Zurich, the city of Geneva and the city of New York are generally open for business;
		
	CHF	  	Swiss Francs, the lawful currency of Switzerland;
		
	Closing Bid Price	  	for Ordinary Shares as of any date, the last closing bid price for such shares on the Principal Market as reported by Bloomberg or, if no such closing bid price is reported for such shares by Bloomberg, the last such closing trade
price of such shares that is reported by Bloomberg;
		
	Closing Date	  	shall have the meaning given to it in clause 4.4(b);
		
	Closing Notice	  	a notice from the Purchaser to the Company in the formset out in Annex 5 pursuant to clause 3;
		
	Commitment Period	  	the period commencing on the date of this Agreement and expiring on the earlier of: (a) the third (3rd) anniversary of the date of this Agreement; and (b) the date on which the Purchaser has subscribed for Ordinary Shares
with an aggregate Subscription Price of CHF 50,000,000 pursuant to this Agreement;
		
	Daily Trading Volume	  	with respect to any Trading Day, the trading volume of the Ordinary Shares on the Principal Market, as reported by Bloomberg, provided that block trades as identified by Bloomberg under the code “RLF” or of a similar type
and trades of 50,000 or more Ordinary Shares shall be disregarded for the purpose of calculating such trading volume;
		
	Designated Officer	  	any director of the Company, the secretary of the Company or such other person as is designated by the board of directors of the Company in writing;
		
	Draw Down Amount	  	the aggregate number of Ordinary Shares stated in each Subscription Notice (which number may be different in each Subscription Notice) that the Company wishes the Purchaser to subscribe for provided that:
		
		  	(a) the Draw Down Amount in each Subscription Notice shall not exceed 700 per cent of the average Daily Trading Volume during the fifteen (15) Trading Days immediately preceding the relevant Notice Date; and

  
 21 

			
		  	 (b) the Draw Down Amount in any Subscription Notice

shall not exceed such amount as, when multiplied by 90 per cent of the Closing Bid Price on the Trading Day immediately prior to the relevant Notice Date and
then added to the aggregate Subscription Price of all the Ordinary Shares subscribed for pursuant to all prior Closing Notices, would be equal to CHF 50,000,000;

		
	Fee	  	has the meaning given in clause 2.4(a);
		
	Floor Price	  	a price set by the Company in each Subscription Notice (which price may be different in each Subscription Notice) below which the Company does not wish to issue Ordinary Shares pursuant to such Subscription Notice. The Parties agree
that at no time shall the Floor Price be set below CHF 0.012, unless agreed by the Company;
		
	Group	  	the Company and its Subsidiaries collectively and anybody corporate which directly or indirectly controls or is under common control with the Company, collectively;
		
	Guidelines	  	means, together, guideline S-02.123 in relation to interbank loans of September 22, 1986 (Merkblatt “Verrechnungssteuer auf Zinsen von Bankguthaben, deren Glaubiger Banken sind
(Interbankguthaben)” vom 22. September 1986), guideline S-02.130.1 in relation to money market instruments and book claims of April 1999 (Merkblatt vom April 1999 betreffend Geldmarktpapiere und
Buchforderungen inlandischer Schuldner), circular letter No. 34 of July 26, 2011 (1-034-V-2011) in relation to deposits
(Kreisschreiben Nr. 34 “Kundenguthaben” vom 26. Juli 2011), circular letter No. 15 of October 3, 2017 in relation to bonds and derivative financial instruments as subject matter of taxation of Swiss federal income tax, Swiss
withholding tax and Swiss stamp taxes (Kreisschreiben Nr. 15 “Obligationen und derivative Finanzinstrumente als Gegenstand der direkten Bundessteuer, der Verrechnungssteuer und der Stempelabgaben” vom 3. Oktober 2017), circular letter
No. 46 of July 24, 2019 (1-046-VS-2019) in relation to syndicated credit facilities (Kreisschreiben Nr.
46betreffendsteuerlicheBehandlungvon Konsortialdarlehen, Schuldscheindarlehen, Wechseln und Unterbeteiligungen vom 24. Juli 2019) and circular letter No. 47 of July 25, 2019
(1-047-V-2019) in relation to bonds (Kreisschreiben Nr. 47 betreffend Obligationen vom 25. Juli 2019), in each case as issued,
amended or replaced from time to time, by the Swiss Federal Tax Administration or as substituted or superseded and overruled by any law, statute, ordinance, court decision, regulation or the like as in force from time to time;

  
 22 

			
	Indemnified Liabilities	  	has the meaning given in clause 9.2;
		
	Indemnified Person	  	Has the meaning given in clause 9.2;
		
	Issue Amount	  	has the meaning given in clause 4.3(b);
		
	Knockout Day	  	any Trading Day during a Pricing Period (a) on which (i) the amount equal to 90 per cent of the Closing Bid Price is less than the applicable Floor Price or (ii) the Ordinary Shares are not traded on the
Principal Market; or (b) in respect of which the Purchaser makes an election in accordance with clause 2.3;
		
	Lien	  	with respect to any asset, any mortgage, lien, pledge, encumbrance, charge or security interest of any kind in or on such asset or the revenues or income therefrom save in so far as they arise or are created by operation of law or
in the normal course of trading;
		
	Listing	  	admission to listing and trading (if applicable) on the Principal Market, and the term Listed shall be construed accordingly;
		
	Listing Rules	  	the rules (including any rules of the Principal Market and any relevant listing authority) applicable to a Listed company from time to time;
		
	Material Adverse Event	  	any event or series of events that has led or may reasonably be expected to lead to (a) any material adverse effect on the business, operations, properties, financial condition or prospects of the Group, taken as a whole,
(b)(i) the Company being prohibited from performing or (ii) a material interference with the authority or ability of the Company to perform, its obligations under or in respect of this Agreement or the Ordinary Shares, (c) the Ordinary
Shares ceasing to be Listed, or (d) the Listing of the Ordinary Shares, or trading in Ordinary Shares on the Principal Market, being suspended for five (5) consecutive Trading Days or more. [***]

  
 23 

			
	Material Change in Ownership	  	any sale or disposal of Ordinary Shares or other transaction or event which results in the officers and directors of the Company for the time being collectively owning less than 5 per cent of the Company’s voting rights
from time to time;
		
	Non-Bank Rules	  	means, together, the 10 Non-Bank Rule and the 20 Non-Bank Rule;
		
	Notice Date	  	the date of delivery, in accordance with clause 9.5, of the applicable Subscription Notice;
		
	Offer	  	has the meaning given in clause 4.2(a);
		
	Ordinary Shares	  	the ordinary registered shares of the Company with such par value as applicable from time to time in issue and the term Ordinary Shareholders shall be construed accordingly;
		
	Paid Amount	  	has the meaning given in clause 2.4(e);
		
	Parties	  	has the meaning set forth on the cover page to this Agreement;
		
	Person	  	an individual or a corporation, a general or limited partnership, a trust, an incorporated or unincorporated association, a joint venture, a limited liability company, a limited liability partnership, a joint stock company, a
government (or an agency or political subdivision thereof) or any other entity of any kind;
		
	Pricing Period	  	the period of fifteen (15) Trading Days, commencing with the first Trading Day immediately following the Notice Date of the applicable Subscription Notice;
		
	Pricing Period Obligation	  	with respect to any Pricing Period, a number of Ordinary Shares equal to the Draw Down Amount divided by 15 and multiplied by the number of Trading Days during the Pricing Period which are not Knockout Days;
		
	Principal Market	  	SIX Swiss Exchange Ltd;
		
	Promissory Note	  	a promissory note to GEMYB in the form set out in Annex 7;
		
	Provided Shares	  	has the meaning given in clause 4.2(a)(i);

  
 24 

			
	Qualifying Bank	  	means (a) any bank as defined in the Swiss Federal Code for Banks and Savings Banks dated November 8, 1934 (Bundesgesetz fiber die Banken and Sparkassen) or (b) a person or entity which effectively conducts
banking activities with its own infrastructure and staff as its principal business purpose and which has a banking license in full force and effect issued in accordance with the banking laws in force in its jurisdiction of incorporation, or if
acting through a branch, issued in accordance with the banking laws in the jurisdiction of such branch, all and in each case within the meaning of the Guidelines;
		
	Required Approvals	  	has the meaning given in clause 5.1(g);
		
	Securities Act	  	the United States Securities Act of 1933, as amended;
		
	Settlement System	  	SIX SIS, the system for electronic settlement of trades in Ordinary Shares on the Principal Market;
		
	Share Providers	  	are listed in Annex 3;
		
	Share Provision	  	has the meaning given in clause 4.2(a)(iii);
		
	Solvent	  	with respect to any Person on a particular date, such Per- son not being deemed unable to pay its debts;
		
	Subscription Notice	  	a notice from the Company to the Purchaser executed by a Designated Officer in the form set out in Annex 4 delivered on any Trading Day during the Commitment Period pursuant to clause 2.1;
		
	Subscription Price	  	with respect to any Pricing Period, 90 per cent of the average of the Closing Bid Prices during such Pricing Period, ignoring for the purposes of such calculation any Knockout Day;
		
	Subsidiary	  	any Person which is a subsidiary of the Company pursuant to article 963 of the Swiss Code of Obligations;
		
	Swiss Withholding Tax	  	means the tax imposed based on the Swiss Federal Act on Withholding Tax of October 13, 1965 (Bundesgesetz fiber die Verrechnungssteuer) together with the related ordinances, regulations and guidelines;
		
	Trading	  	trading of the Ordinary Shares on the Principal Market;
		
	Trading Day	  	a day on which the Principal Market is open and remains open for not less than five (5) hours;
		
	Warranties	  	the statements made in clause 5.1.

  
 25 

 Annex 2 — Contact Details of the Purchaser and GEM Management 

 

					
	Name	  	 Address and Facsimile

Number
	  	 Percentage Allocation of
 Ordinary
Shares and
 Warrants

	GEM GLOBAL YIELD LLC SCS	  	 GEM GLOBAL YIELD LLC
 SCS c/o GEM Investments
America LLC
 390 Park Avenue, 7th Floor
 New York

NY 10022
 USA

 
 Tel.: 001 (212) 582 3400

Fax: 001 (212) 265 4035
  

FAO: Chris Brown
 cbrown@gemny.com
	  	100 per cent
			
	GEM Yield Bahamas Ltd	  	 GEM Yield Bahamas Ltd
 Office of Lennox Paton
Corporate Services Limited
 Bayside Executive Park
 Building
3
 West Bay Street
 P.O. Box
N-4875
 Nassau
 Island
of New Providence
 Commonwealth of the Bahamas
  

Tel.: 001 (212) 582 3400
 Fax: 001 (212) 265 4035

 
 FAO: Chris Brown

cbrown@gemny.com
	  	None

  
 26 

 Annex 3 — Details of Share Providers 

[***] 

  
 27 

 Annex 4 — Form of Subscription Notice 

Subscription Notice 
 To: GEM GLOBAL
YIELD LLC SCS 
 We refer to the share subscription facility agreement (the Agreement) dated January 20, 2021 between (amongst others) us, GEM Yield
Bahamas Ltd (GEMYB) and GEM GLOBAL YIELD LLC SCS. Terms defined in the Agreement have the same meaning herein. This Subscription Notice is being delivered to you pursuant to clause 2.1 of the Agreement. 

[We understand that the Closing Bid Price for the Trading Day immediately preceding the date of this notice was CHF [•]. 

The Draw Down Amount applicable to this Subscription Notice shall be [•] Ordinary Shares. 

The Floor Price applicable to this Subscription Notice shall be CHF [•]. 

The first Trading Day of the Pricing Period shall be [•]. 

We hereby certify that all conditions precedent to the delivery of this Subscription Notice pursuant to the Agreement have been satisfied (or waived in
writing by you.) 
  

							
	Purchaser’s Name	 	Allocated Proportion
	___________________________________________________	 	___________________________________________________
	GEM GLOBAL YIELD LLC SCS	 	[100 per cent]
		
	Signed by: __________________________________________	 	Signed by: __________________________________________
		
	Name: _____________________________________________	 	Name: _____________________________________________
		
	Date: ______________________________________________	 	Date: ______________________________________________
		
	For and on behalf of	 	For and on behalf of
		
	RELIEF THERAPEUTICS Holding SA	 	RELIEF THERAPEUTICS Holding SA

  

  
 28 

 Annex 5 — Form of Closing Notice 

Closing Notice 
 To: RELIEF
THERAPEUTICS Holding SA 
 Attention: Board of Directors 

We refer to the share subscription facility agreement (the Agreement) dated January 20, 2021 between us, GEM Yield Bahamas Ltd, the Share Providers and
yourselves and to the Subscription Notice delivered to us on [•] 20[•]. Terms defined in the Agreement have the same meaning herein. 
 We hereby
give you notice pursuant to clause 3 of the Agreement that we accept the Subscription Notice for [•] Ordinary Shares, being [•] per cent of the Ordinary Shares stated therein. [The reason that such number of Ordinary Shares represents a
smaller/greater number than the number of Ordinary Shares set forth in the Subscription Notice is as follows: [•].] 
 The average of the Closing Bid
Prices in the Pricing Period (excluding any Closing Bid Prices on Knockout Days) is CHF [•] and the resulting Subscription Price is CHF [•] [•] per cent of such average Closing Bid Price). The aggregate Subscription Price pursuant to
this Closing Notice is therefore CHF[•]. 
 Copy extracts from Bloomberg showing each of the Closing Bid Prices during the Pricing Period are attached.

 Please deliver such Ordinary Shares in accordance with the following instructions: [•]. 

Electronic book entry transfer requested (check one) (1) YES ☐ NO ☐ 

Settlement System Participant ID: ________________________ 

Settlement System Account ID: ________________________ 
  

			
	Signed by:	 	 

 
			
		
	Name:	 	 

 
			
		
	Date:	 	 

 
			
	
	For and on behalf of
	
	GEM GLOBAL YIELD LLC SCS

  
 29 

 Annex 6 — Form of Assignment and Transfer by the Purchaser 

Assignment and Transfer by the Purchaser 

This Assignment and Transfer is made on [•] 20[•] 

between 
 (1) GEM GLOBAL YIELD LLC SCS (together with its
permitted successors and assigns), a company incorporated under the laws of Luxembourg whose registered office is at 412F, route d’Esch, L-2086 Luxembourg (the Assignor); 

(2) RELIEF THERAPEUTICS Holding SA, a Company registered in Switzerland whose registered address is at Avenue de Secheron 15, 1202 Geneve, Switzerland
(the Company); and 
 (3) [•], [details] (the Assignee). 

Whereas 
 (1) By a share subscription facility agreement
dated January 20, 2021 (the Agreement), the Assignor granted to the Company an option to require the Assignor to subscribe, on the terms and subject to the conditions set out in the Agreement, for up to an aggregate of CHF 50,000,000 in value
of Ordinary Shares. 
 (2) The Assignor wishes to transfer its rights and obligations under the Agreement to the Assignee in accordance with clause 9.8 of
the Agreement. 
 It is agreed: 
  

	1.	 Definitions 

Words and expressions defined in the Agreement shall have the same meaning herein. 
  

	2.	 Assignment and Transfer 

The Assignor hereby assigns and transfers to the Assignee the Agreement, together with all its rights deriving under the Agreement. The Company hereby releases
the Assignor from all of its obligations pursuant to the Agreement and the Assignee hereby agrees to assume responsibility for the performance of all such obligations. The Assignor hereby releases the Company from all its obligations pursuant to the
Agreement and the Company hereby agrees that the Assignee shall be entitled to enforce all such obligations directly against the Company as if the Assignee were the Purchaser named in the Agreement. 

 

	3.	 Warranties and Undertakings 

3.1 The Assignee hereby represents, warrants and undertakes to the Company that it shall perform and comply with all terms of the Agreement in all respects as
if it were the Purchaser originally named therein. 

  
 30 

 3.2 Without prejudice to the generality of the foregoing, the Assignee hereby represents, war- rants and undertakes to the Company that the statements set out in clause 6 of the Agreement (which statements shall be deemed to refer to the Assignee as the Purchaser) are now and will be true and accurate in
all respects as at each Notice Date and at each Closing Date and on each date on which Ordinary Shares are due to be subscribed by and issued to the Assignee pursuant to the Agreement. 

 

	4.	 Governing Law 

This Assignment and Transfer as well as any dispute or claim arising out of or in connection with this Assignment and Transfer shall be governed by the laws of
Switzerland without giving effect to any choice of law or conflict of law provision or rule that would cause the application of the laws of any jurisdiction other than Switzerland. Any dispute, controversy or claim arising out of, in connection with
or relating to this Assignment and Transfer (or subsequent amendments thereof), including without limitation, disputes, controversies or claims regarding its existence, validity, invalidity, breach or termination, shall be finally resolved by
arbitration in accordance with the Swiss Rules of International Arbitration of the Swiss Chambers’ Arbitration Institution in force on the date on which the Notice of Arbitration (as such term is defined in the Swiss Rules of International
Arbitration of the Swiss Chambers’ Arbitration Institution) is submitted in accordance with such rules. The number of arbitrators shall be one. The seat of the arbitration shall be Zurich. The arbitral proceedings shall be conducted in English.

 [signatures on the next page] 

  
 31 

 In witness whereof the Company, the Assignor and the Assignee have executed and delivered this Assignment
and Transfer the day and year first before written. 
  

					
	RELIEF THERAPEUTICS Holding SA	  		  	
			
	 	  		  	 
	Name:	  		  	Name:
	Function:	  		  	Function:
			
	GEM Global Yield LLC SCS	  		  	
			
	 	  		  	
	Name: Christopher F. Brown	  		  	
	Function: Manager	  		  	
			
	[the Assignee]	  		  	
			
	 	  		  	
	Name:	  		  	
	Function:	  		  	

  
 32 

 Annex 7 — Form of Promissory Note 

Promissory Note 
 of

 RELIEF THERAPEUTICS Holding SA 

Date: January 20, 2021 
 In consideration for entry by GEM
Yield Bahamas Ltd (the Beneficiary) into the Share Subscription Facility Agreement entered into between RELIEF THERAPEUTICS Holding SA, a company limited by shares registered in Switzerland whose registered address is at Avenue de Secheron 15, 1202
Geneve, Switzerland (the Company), the Share Providers, GEM GLOBAL YIELD LLC SCS and the Beneficiary on or about the date of this Promissory Note, the Company hereby promises to pay to the order of the Beneficiary the principal sum of 

CHF 1,250,000 (the Fee) 
 on demand on or
after the first few drawdowns (the Payment Date) together with interest on such principal sum at a rate of one hundred (100) basis points per annum above the base rate of Barclays Bank PLC from time to time. Interest at such rate shall
accrue daily from the Payment Date, shall be calculated on the basis of the actual number of days elapsed in a year of 365 days, shall be compounded monthly and shall be payable on demand. If the applicable base rate is less than zero, the
applicable base rate shall be deemed zero. If on the expiry of twelve (12) months from the date of the Agreement no Closing Date has occurred, the Company shall pay the total outstanding amount of the applicable Fee to the Beneficiary. It is
therefore expressly acknowledged by the Company that the Fee shall be due on the first anniversary of the Agreement, regardless of whether a Closing Date has occurred before that date. 

This Promissory Note and any dispute or claim arising out of or in connection with it or its subject matter (including
non-contractual disputes or claims) is governed by and shall be construed and take effect in accordance with the laws of Switzerland without giving effect to any choice of law or conflict of law provision or
rule that would cause the application of the laws of any jurisdiction other than Switzerland. Any dispute, controversy or claim arising out of, in connection with or relating to this Promissory Note (or subsequent amendments thereof), including
without limitation, disputes, controversies or claims regarding its existence, validity, invalidity, breach or termination, shall be finally resolved by arbitration in accordance with the Swiss Rules of International Arbitration of the Swiss
Chambers’ Arbitration Institution in force on the date on which the Notice of Arbitration (as such term is defined in the Swiss Rules of International Arbitration of the Swiss Chambers’ Arbitration Institution) is submitted in accordance
with such rules. The number of arbitrators shall be one. The seat of the arbitration shall be Zurich. The arbitral proceedings shall be conducted in English. 

Defined terms used in this Promissory Note and not defined therein shall have the same meaning as in the Share Subscription Facility Agreement executed
between the Company, the Share Providers, the Beneficiary and GEM GLOBAL YIELD LLC SCS on the date hereof. 

  
 33 

 In witness whereof this Promissory Note is executed on the date first above written. 

 

	
	RELIEF THERAPEUTICS Holding SA
	
	 
	Name:
	Function:

  
 34EX-10.6

 Exhibit 10.6 

CERTAIN CONFIDENTIAL INFORMATION INDICATED BY “[***]” HAS BEEN OMITTED FROM THE FILED COPY OF THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT
MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
 COLLABORATION AGREEMENT 

This COLLABORATION AGREEMENT (this “Agreement”) is made and entered into as of November 23, 2021 (the “Effective
Date”), by and between InveniAI LLC, a wholly owned subsidiary of [***], a Delaware Incorporated located at 2614 Boston Post Road, Suite 33B, Guilford, CT 06437 (“InveniAI”) and Relief Therapeutics Holding SA, a Switzerland
corporation located at Bâtiment F2/F3, Avenue de Sécheron 15, 1202 Genève, Switzerland (“Relief”). 

BACKGROUND 

WHEREAS, Relief is a biopharmaceutical company whose objective is to provide patients with therapeutic RELIEF in serious diseases with
high unmet medical need. They focus on clinical-stage programs based on molecules with a history of clinical use (well-established safety and tolerability) and either initial human activity or efficacy data (proof of concept) or a strong scientific
rationale. This allows them to identify molecules where clinical development can be swift (trials with evaluation windows of weeks or months) and cost effective. Relief is seeking technology enabled artificial intelligence (AI) solution from
InveniAI to generate testable hypotheses and product concepts (repurposing and reformulation candidates) across rare diseases; 

WHEREAS, InveniAI has developed a platform for the identification of potential pharmaceutical product opportunities called Pharma Big
Data Innovation Lab (“Platform”), consisting of (i) its proprietary AlphaMeld® platform, which is a cloud-based Artificial Intelligence platform that utilizes proprietary
machine learning and deep learning based neural networks to identify product opportunities in therapeutic areas, (ii) cross-functional teams at its Integrated Center of Excellence, and (iii) domain expertise, to generate novel
pharmaceutical opportunities and identify potential approaches to development of such concepts; 
 WHEREAS, InveniAI and Relief
desire to initiate a strategic collaboration, wherein InveniAI will use its Platform to help navigate the volume of data for all regulatory agency approved drugs and their associated active ingredients (Active Pharmaceutical Ingredient (API)) and
associate to potential rare disease indications, “API-disease combinations” for IND-enabling, development and commercialization by Relief (“Product
Concepts”). InveniAI will prioritize top Product Concepts, associated diseases, scientific package and evidence to support the hypotheses. 

NOW, THEREFORE, In consideration of the mutual promises and conditions in this Agreement, and for other good and valuable
consideration, the sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 
 1. DEFINITIONS 

Unless the context otherwise requires, the terms in this Agreement with initial letters capitalized, will have the meanings set forth below,
or the meaning as designated in the indicated places throughout this Agreement. 

 1.1. “AB Rated Product” means a product approved by a regulatory
agency that has determined the product to be bioequivalent to an existing or already-approved product identified as an Approved Product Concept. 

1.2. “Accepted Product Concept” has the meaning ascribed to it in Section 2.5.3. 

1.3. “Additional Product Concepts” has the meaning ascribed to it in Section 2.5.3. 

1.4. “Affiliate” of a Party means any Person that, directly or indirectly, through one or more intermediaries,
controls, is controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used in this Section 1.2, “control” will mean (i) direct or indirect beneficial ownership
of at least fifty percent (50%) of the voting share capital or other equity interest in such Person or (ii) the power to direct the management of such Person by contract or otherwise. 

1.5. “Approved Active Pharmaceutical Ingredients (APIs)” has the meaning ascribed to it in the Background to this
Agreement. 
 1.6. “Bankruptcy Laws” means Section 365(n) of Title 11 of the United States Code, the U.S.
Bankruptcy Code and any foreign counterparts thereto. 
 1.7. [***] 

1.8. “Business Day” means any day Monday through Friday, provided that if an activity to be performed or an event to
occur falls on a Friday, Saturday, Sunday or any other day which is recognized as a national holiday in New York, New York or in Genève, Switzerland, then the activity may be performed or the event may occur on the next day that is not a
Friday, Saturday, Sunday or such nationally recognized holiday. 
 1.9. “Commercialization Payment” has the meaning
ascribed to it in Section 5.3. 
 1.10. “Commercially Reasonable Efforts” means, with respect to the efforts to
be expended by a Party pertaining to a particular objective under this Agreement, the efforts and resources commonly used by a similarly situated (with respect to size, stage of development and assets) company for similar products or product
candidates, as applicable, to accomplish a similar objective under similar circumstances exercising reasonable business judgment “Confidential Information” means any confidential or proprietary information or data disclosed by either Party
or its Affiliates or Representatives under this Agreement, whether provided in written, oral, graphic, visual, electronic or other form, including any non-public information relating to the Product Concepts,
the Development Program, development efforts, new inventions, sources of materials, cost, pricing and other financial information, and IP Rights and Patent information, in each case that is marked or otherwise identified as proprietary or
confidential at the time of disclosure, or that the receiving Party should reasonably know to be confidential or proprietary. 

1.11. “Control” or “Controlled” means, with respect to any IP Rights, the possession (whether by
ownership, license, sublicense or contract, other than pursuant to this Agreement) by a Party or its Affiliates of the right to grant to another Party access, license, sublicense, or other right as provided herein, without violating the terms of any
agreement or other arrangement, existing before the Effective Date, with any Third Party. 

  

			
		  	2

 1.12. “Deliverables” includes Product Concepts, Accepted Product
Concepts, Draft Report, Final Report and any output of the Development Program insofar as it is provided for in Exhibit I and/or incorporates or relies on Relief Confidential Information and Relief IP 

1.13. “Development Program” has the meaning ascribed to it in Section 2.5.1. 

1.14. “Discloser” means the Party, or its Affiliates or Representatives, which discloses its own Confidential
Information. 
 1.15. “Draft Report” has the meaning ascribed to it in Section 2.2. 

1.16. “Effective Date” has the meaning ascribed to it in the Preamble. 

1.17. “EU5 Countries” means the United Kingdom, Germany, France, Spain and Italy. For clarity, the United Kingdom
remains EU5 Countries after so called Brexit for the purpose of this Agreement. 
 1.18. “Exclusion List” has the
meaning ascribed to it in Section 2.3. 
 1.19. “Final Report” has the meaning ascribed to it in
Section 2.2.3 
 1.20. “First Commercial Sale” means, with respect to a Accepted Product Concept, the first
commercial sale of such Accepted Product Concept by or on behalf of Relief to a Third Party (including wholesalers or distributors), after receipt of Regulatory Approval for such Accepted Product Concept. 

1.21. “Force Majeure Event” has the meaning ascribed to it in Section 9.5. 

1.22. “FTO” has the meaning ascribed to it in Section 2.2.4. 

1.23. “Identification Period” shall mean a period of twelve (12) months from the InveniAI’s receipt of the
Product Concept Identification Fees. 
 1.24. “IND” means Investigational New Drug. 

1.25. “Indication Focus” has the meaning ascribed to it in Section 2.1.2. 

1.26. “InveniAI Indemnitees” has the meaning ascribed to it in Section 9.2.2. 

1.27. “InveniAI IP” means all IP Rights owned or Controlled by InveniAI or its Affiliates either (i) prior to the
Effective Date, or (ii) independent of the Development Program or this Agreement (iii) Product Concepts other than Accepted Product Concepts developed under this Agreement. 

  

			
		  	3

 1.28. “IP Rights” means all vested, contingent and future
intellectual property rights including: (i) all inventions, materials, compounds, compositions, substances, methods, processes, techniques, know-how, technology, data, information, discoveries and
materials, including ideas, concepts, formulas, assays, practices, processes, software, devices, techniques, procedures, designs, compositions, constructs, compounds, plans, applications, research, preclinical and clinical data, regulatory
information, manufacturing process, scale-up and other technical data, reports, documentation and samples, including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and
analytical, pre-clinical, clinical, safety, manufacturing and quality control data and information, as well as study designs and protocols; assays and biological methodology and other results of any nature
whatsoever, and any Patents, trade secrets, confidential information, proprietary processes, or industrial rights directly or indirectly deriving therefrom; (ii) all trademarks, service marks, copyrights, designs, trade styles, logos, trade
dress, and corporate names, including all goodwill associated therewith; and (iii) any work of authorship, regardless of copyrightability, all compilations and all copyrights. 

1.29. “Joint Steering Committee” or “JSC” means the joint steering committee established by the
Parties as set forth in Section 2.4.1. 
 1.30. “Losses” has the meaning ascribed to it in Section 9.2.1.

 1.31. “Milestone Event” has the meaning ascribed to it in Section 5.2. 

1.32. “Milestone Fees” has the meaning ascribed to it in Section 5.2. 

1.33. “Milestone Payment” has the meaning ascribed to it in Section 5.2. 

1.34. “Mutual NDA” has the meaning ascribed to it in Recitals. 

1.35. “Net Sales” means the actual amounts received by Relief or its Affiliates from the sale by Relief, its
Affiliates or their licensees of the Accepted Product Concept(s) in the United States, EU5 Countries and Japan to Third Parties, less 

1.35.2. net of any of the following to the extent included in such amounts: (a) normal and customary trade and quantity discounts
actually given; and, in case of returns or rejections of the product(s), the associated credits and price adjustments; and (b) discounts, rebates, reimbursements, chargeback payments or commissions allowed or granted, and administrative fees
paid, to government agencies, managed health care organizations or trade customers, including wholesalers, health care administrators, patient assistance or similar programs, pharmacy benefit managers, health care institutions including hospitals
other distributors, pharmacies and other retailers, buying groups, health maintenance organizations, national, state/provincial, local, and other governments, their agencies and purchasers and reimbursers, any other providers of health insurance
coverage, and group purchasing organizations or other chain buying groups; and 
 1.35.2. (a) freight, postage, shipping, customs
duties and insurance charges; and (b) sales, value-added, and excise taxes, tariffs, and other taxes and government charges invoiced to Third Parties without markup; and (c) fees or other charges paid under the Patient Protection and
Affordable Care Act of 2010 or other similar legislation in foreign countries and d) any other items actually deducted from gross invoiced sales amounts as reported by Relief or its Affiliates in their financial statements in accordance with their
accounting standards, applied on a consistent basis. 

  

			
		  	4

 1.36. “Opt-in Fee” has the
meaning ascribed to it Section 5.2. 
 1.37. “Option Pool” has the meaning ascribed to it in
Section 2.2.3. 
 1.38. “Parties” means Relief and InveniAI and “Party” means either of Relief
or InveniAI. 
 1.39. “Patent(s)” means (a) any and all national, regional and international patents,
certificates of invention, applications for certificates of invention, priority patent filings and patent applications, including provisional patent applications, and (b) any renewal, divisional, continuation (in whole or in part), or request
for continued examination of any of such patents, certificates of invention and patent applications, and any and all patents (including utility models, petty patents and design patents) or certificates of invention issuing thereon, and any and all
reissues, reexaminations, extensions, divisions, renewals, substitutions, confirmations, registrations, revalidations, revisions, and additions of or to any of the foregoing. 

1.40. “Person” means any individual, corporation, partnership, limited liability company, trust, governmental entity,
or other legal entity of any nature whatsoever. 
 1.41. “Platform” has the meaning ascribed to it in the Recitals.

 1.42. “Product Concept” has the meaning ascribed to it in the Recitals. 

1.43. “Product Concept Identification Fees” has the meaning ascribed to it in Section 5.1. 

1.44. “Purpose” has the meaning ascribed to it in Section 8.1. 

1.45. “Recipient” means the Party receiving Confidential Information from the other Party or its Affiliates or
Representatives. 
 1.46. “Regulatory Development Path” has the meaning ascribed to it in Section 2.1.3. 

1.47. “Regulatory Approval” means the approval of a governmental authority necessary to commercially distribute, sell,
market and use a Accepted Product Concept in a given country or regulatory jurisdiction in accordance with applicable laws and regulations. 

1.48. “Reformulation Opportunity” has the meaning ascribed to it in Section 2.1.1. 

1.49. “Re-Innovation and Reformulation Opportunity” has the meaning ascribed
to it in Section 2.1.1. 
 1.50. “Relief Indemnitees” has the meaning ascribed to it in Section 9.2.1.

 1.51. “Relief IP” means (a) all IP Rights owned or Controlled by Relief and its Affiliates (i) prior to
the Effective Date, (ii) independent of the Development Program or this Agreement, or (iii) generated without the use of any InveniAI IP or InveniAI Confidential Information and (b) all IP Rights for (i) the Accepted Product
Concepts and any content related to Accepted Product Concepts in the Final Report, and/or; (ii) any output of the Development Program insofar as it incorporates or relies on Relief Confidential Information and Relief IP. 

  

			
		  	5

 1.52. “Representatives” means employees, officers, agents,
subcontractors, consultants, Affiliates and/or any other Person acting on a Party’s behalf, individually or collectively, and which will be exposed to Confidential Information. 

1.53. “Senior Executive” has the meaning ascribed to it in Section 9.7. 

1.54. “Strategic Considerations” has the meaning ascribed to it in Section 2.1.4. 

1.55. “Successor” means any successor to a Party by way of (i) sale of all or substantially all of the assets of
a Party, (ii) stock sale or share exchange, or (iii) merger or similar reorganization transaction. 
 1.56.
“Term” has the meaning ascribed to it in Section 7.1. 
 1.57. “Third Party Claim” has the
meaning ascribed to it in Section 9.2.1. 
 1.58. “Third Party” means any Person other than Relief, InveniAI or
their respective Affiliates. 
 2. IDENTIFICATION AND DELIVERY OF PRODUCT CONCEPTS 

2.1. Identification Period. InveniAI, during the Identification Period, will utilize its Platform, and may rely on or
incorporate Relief IP and Relief Confidential Information, to: identify Product Concepts across rare diseases that may be suitable for Relief to (a) validate in animal model systems: and (b) conduct
IND-enabling studies on the Accepted Product Concepts. InveniAI shall use Commercially Reasonable Efforts to identify Product Concepts in accordance with the timeline described in Exhibit I hereof. Relief may
give reasonable cooperation and assistance in InveniAI’s identification activities. InveniAI will provide a monthly overview on its efforts and activities performed during the Identification Period. The Product Concepts will encompass the
following considerations: 
 2.1.1. Active Pharmaceutical Ingredients (APIs) of all approved drugs: 6000+ 

 

	 	•	 	 Re-Innovation and Reformulation Opportunity: Alignment of existing
API into a new indication with/without new formulation that offers benefit over existing drug by addressing significant unmet need 

  

	 	•	 	 Reformulation Opportunity: Same API, same indication with a novel formulation to offer benefit over
existing drug by addressing significant unmet need (for example [***]) 

 2.1.2. Indication Focus on
7000+ orphan diseases 
 2.1.3. Regulatory Development Path via 505(b)2 development 

  

			
		  	6

 2.1.4. Strategic Considerations: 

 

	 	•	 	 Concepts in alignment with Relief’s existing infrastructure: 

 

	 	•	 	 Formulation, development and commercial 

 

	 	•	 	 Defined regulatory path with end points defined with the FDA 

 

	 	•	 	 Availability of patient advocacy group 

 

	 	•	 	 Low investment for clinical trial and quicker path to market (3-5 years)

 2.2. Deliverables. InveniAI, by within twelve (12) months of the Effective Date will submit
for Relief’s review a draft report (the “Draft Report”) that: 
 2.2.1. Identifies InveniAI’s hypotheses;

 2.2.2. The landscape of up to six (6) Product Concepts identified and prioritized; 

2.2.3. Provides target product profiles (TPPs) including design of animal proof of validation study design for up to six
(6) Product Concepts (hereinafter the “Option Pool”). 
 2.2.4. includes a Freedom to Operate analysis
(“FTO”), that ascertains by execution of a proper patent and prior art search if the Product Concepts can be used by Relief for the purpose of their clinical development or commercialization worldwide. The FTO is only restricted to
patent searches and does not include legal recommendation 
 Relief may make comments on the Draft Report within sixty (60) days or other period if
agreed by the Parties from receipt of Draft Report and InveniAI will create and submit a revised report that makes commercially reasonable efforts to address Relief’s comments within thirty (30) days or other period if agreed by the
Parties from receipt of Relief’s comments. (the “Final Report”). 
 The Parties agree that, in case InveniAI’s activities under
Section 2.1 deviate from the timeline described in Exhibit I hereof, each Party shall have the right to request the Joint Steering Committee to discuss the reasons for delay and to discuss and agree in good faith about the required changes to
the timeline according to the provision of Section 2.4. 
 2.3. Exclusion from Collaboration. InveniAI provides in
the Exhibit II to this Agreement to Relief the list of rare diseases related to [***] (the “Exclusion List”) to avoid the conflict with InveniAI’s and its sister Affiliate, [***] internal projects. The Exclusion List shall be
out of the scope of this Collaboration Program. 
 2.4. Governance 

2.4.1. The Joint Steering Committee (JSC) shall have a total of six (6) members, with three (3) members appointed by
Relief and three (3) members appointed by InveniAI to (i) monitor the progress of the collaboration, (ii) ensure the coordination of project and regulatory activities by the respective Parties and timely completion of all work
(iii) discuss the selection of Product Concepts. JSC shall meet monthly or as otherwise agreed by the Parties, but no less than six (6) times per year which meetings shall not be more than eight weeks apart. Relief will have the final
decision authority on such issues that relate to this collaboration. 
 2.4.2. The JSC shall be formed within the term of four
(4) calendar weeks from the Effective Date. 

  

			
		  	7

 2.4.3. The JSC will be able to establish and delegate duties to sub-committees such as joint research committees to oversee and direct particular projects or activities at an appropriate time. 

2.5. Product Concept Evaluation. 

2.5.1. The Parties shall collaborate through the JSC and as otherwise agreed to by the Parties for InveniAI’s identification
activities for the Product Concepts during the Identification Period and during the period set forth in Section 2.6 (the “Development Program”). 

2.5.2. Upon delivery of Final Report, Relief will provide a written notice to exercise the right to acquire one or more Product
Concepts from the Final Report within a 180-day period. Notwithstanding the foregoing, in case Relief is required to acquire or license-in any IP Right from Third
Parties in order to be able to get ownership rights for one or more Product Concepts, the Parties shall discuss and agree in good faith about any longer period of time for Relief to provide the written notice required to get ownership rights for any
selected Product Concept. 
 2.5.3. Upon exercising the right and payment, Relief will get ownership rights for the Product Concepts
(“Accepted Product Concepts”). Save the longer period of time agreed pursuant to Section 2.5.2, if Relief does not acquire any Product Concept from the Option Pool within 180 days from delivery of the Final Report, InveniAI
will provide 2 additional Product Concepts (the “Additional Product Concepts”) for consideration within an additional term of 90 days. Save any longer period to be agreed between the Parties according to the provision of
Section 2.5.2, which shall also apply in relation to the Additional Product Concepts, Relief will have a 180-day period from receiving the Additional Product Concepts to decide whether to exercise its
right to acquire the Additional Product Concepts and provide written notice of same. Relief will have no right to acquire the Product Concepts provided in the initial Final Report, in case of requesting additional 2 Product Concepts. 

2.5.4. Relief will have the exclusive rights, inter alia, to continue IND-enabling
preclinical study and further development of the Accepted Product Concepts only. Accepted Product Concepts are subject to payments of success based milestones in Section 5.2. The Parties agree that Relief shall be responsible for and bear all
costs and expenses for intellectual property protection, development and commercialization of any Accepted Product Concepts. Nothing contained in this Agreement will be deemed to be a warranty by either Party that such Party can or will be able to
obtain Patents based on the activities conducted under the Development Program. 
 2.5.5. At all times, Relief and its Affiliates
shall have the right, but not the obligation, to totally or partially license the IP rights, commercial rights and any related rights on the Accepted Product Concepts to their licensees, subject to Relief’s payment obligations under Sections
5.2 and 5.3. Subject to 9.12.3, Relief and its Affiliate’s licensee shall benefit at all time of a perpetual license right under the InveniAI IP according to Section 4.1.6. 

2.6. Term of Development Program. Subject to Section 2.5.3, the Development Program shall expire upon either of the
earlier 1) the date Relief selects Accepted Product Concepts for further development and commercialization; or 2) One hundred and eighty days (180) days following the delivery of Final Report. 

  

			
		  	8

 3. EXCLUSIVITY 

3.1. Exclusivity. In addition to the restriction set out in Section 4.1 below, InveniAI shall not, itself or through
any of its Affiliates or any Third Party, research, develop, make, use, market, license, offer to sell, sell or otherwise commercialize any such Relief IP, including the Accepted Product Concepts and any subject matter related to Accepted Product
Concepts in the Final Report, and the Final Report’s core content regarding the Product Concepts (API-disease combinations). 

4. INTELLECTUAL PROPERTY 

4.1. Ownership of Product Concepts and IP Rights Developed under this Agreement. 

4.1.1. Subject to Section 4.1.2, as between the Parties, Relief shall be the sole and exclusive owner of all rights, title and
interest in and to the Accepted Product Concepts and any content related to Accepted Product Concepts in the Final Report. 
 4.1.2.
As between the Parties, InveniAI shall be the sole and exclusive owner of all rights, title and interest in and to any improvements or enhancements of the existing InveniAI’s AI methodologies and technology used by InveniAI to perform its
obligations hereunder. 
 4.1.3. Each Party shall take such actions, including executing and delivering IP Rights assignment
agreements, as are reasonably requested by the other Party to evidence or perfect the allocation of rights set forth in this Section 4.1. 

4.1.4. Each Party may pursue intellectual property protection for its IP Rights as it deems appropriate and at its own expense. 

4.1.5. Each Party may license, transfer, assign or otherwise dispose its own IP Rights freely without any restriction unless otherwise
specifically set forth in this Agreement. 
 4.1.6. Subject to Section 9.12, InveniAI grants Relief a non exclusive, upon paying
the Opt-in Fee, sub-licensable, free of charge, non transferable licence under the InveniAI IP to the extent necessary to allow Relief to exploit the Accepted Product
Concepts and any content related to Accepted Product Concepts in the Final Report worldwide. 
 4.2. Ownership of IP Rights
Developed Outside of this Agreement. 
 4.2.1. InveniAI has and shall retain all right, title and interest in and to, the
InveniAI IP, subject to the rights and licenses granted to Relief and its Affiliates as expressly set forth in this Agreement. 

  

			
		  	9

 4.2.2. Relief has and will retain all right, title and interest in and to, the Relief
IP, subject to the rights and licenses granted to InveniAI and its Affiliates as expressly set forth in this Agreement. 
 4.2.3.
Except for the rights and licenses expressly granted in this Agreement, InveniAI retains all rights under its intellectual property, including the InveniAI IP, and Relief retains all rights under its intellectual property, including the Relief IP,
and no rights shall be deemed granted by one Party to the other Party by implication, estoppel or otherwise. 
 4.3.
Development Program License Grants. Relief hereby grants to InveniAI and its Affiliates a worldwide, non-exclusive, non-transferable and royalty-free
license, without the right to sublicense, under Relief IP during the term of the Development Program only to the extent necessary or useful for InveniAI and its Affiliates to use the Relief IP to identify potential Product Concepts for Relief. For
clarity, a) InveniAI and its Affiliates are not granted any right or license to use the Relief IP to identify compounds or product opportunities for InveniAI or any of its Affiliates or a Third Party and b) upon expiry of the Development Program the
license shall be automatically terminated. 
 5. FEES AND PAYMENTS 

5.1. Product Concept Identification Fees. In consideration of InveniAI’s work to identify Product Concepts to Relief
during the Identification Period, Relief shall pay InveniAI, [***] due upon signing this Agreement. For the avoidance of doubt, InveniAI will have no obligation to commence work under this Agreement unless and until Relief pays the Product Concept
Identification Fees. 
 5.2. Milestone Fees. In consideration for the rights granted to Relief hereunder, Relief will
make the following payments (each a “Milestone Payment”) to InveniAI for each milestone associated with Accepted Product Concept (each a “Milestone Event”). 

 

					
	Success Based Milestones by Relief for clinical development and commercialization for Accepted Product Concepts:
	Milestones paid to InveniAI	 	  
 Transfer Fee upon Relief’s exercise of the option to acquire the
IP Rights related to Accepted Product Concepts (“Opt-in Fee”)
	 	  
 [***]

	 	  
 Upon issuance or allowance of a valid set of patent claims pertaining
to the Accepted Product Concept by the United States Patent & Trademark Office (USPTO)
	 	  
 [***]

	 	  
 Upon successful completion of a Phase 3 program
	 	  
 [***]

	 	  
 Regulatory Approval for the Accepted Product Concept in United
States
	 	  
 [***]

	 	  
 Regulatory Approval for the Accepted Product Concept in EU5
Countries
	 	  
 [***]

	 	  
 Regulatory Approval for the Accepted Product Concept in Japan
	 	  
 [***]

	 	  
 First Achievement of annual Net Sales related to the Accepted Product
Concept: $500M
	 	  
 [***]

	 	  
 First Achievement of annual Net Sales related to the Accepted Product
Concept: $1000M
	 	  
 [***]

  

			
		  	10

 5.3. Commercialization Payment. In further consideration for the
services performed for and the rights granted to Relief hereunder, beginning with the First Commercial Sale of each Accepted Product Concept, Relief shall pay to InveniAI in each of the United States, EU5 Countries and Japan and ending on the
earlier date of (a) termination of all valid claims of Patents covering a product preventing a Third Party from selling an AB Rated Product in the United States or comparable rating outside of United States, in each of the United States, EU5
Countries, Japan, or (b) the tenth (10th) anniversary of the First Commercial Sale in each of the United States, EU5 Countries and Japan, a royalty rate of [***] ([***])% on Net Sales of the Accepted Product Concept (“Commercialization
Payment”) payable to InveniAI sixty (60) days from each financial quarter closing. 
 5.4. Payment.
Relief will report all milestones stated in Sections 5.2 and 5.3 to InveniAI within thirty (30) Business Days of meeting the milestone event. InveniAI will provide an invoice for each payment to Relief appropriately, and Relief will make such
payment within sixty (60) days after receipt of the invoice. All payments and expense reimbursements shall be made by Relief in United States Dollars by wire transfer of immediately available funds to an account designated in writing by
InveniAI. Any payments made more than thirty (30) days after the date due shall bear interest at the rate permitted by law. 

5.5. Taxes. All payments of any amounts pursuant to this Agreement must comply with applicable tax withholding
obligations. After reasonable advance notice to the extent practical, Relief has the right to withhold and pay to applicable taxing authorities any amounts required to be withheld by any applicable laws from amounts payable to InveniAI. Relief will
promptly provide InveniAI with all relevant information and documentation with respect to the amounts withheld. For clarity, in no event will a) will the withholding payment be summed-up to the amount payable
to InveniAI and b) Relief be responsible for the payment of taxes levied on the income of any other Party pursuant to this Section 5.5. 

6. REPRESENTATIONS AND WARRANTIES 

6.1. Reciprocal Representations. Each Party hereby represents and warrants to the other Party that: 

6.1.1. it has the full power and authority to enter into this Agreement and to perform its obligations hereunder, and all required
corporate approvals have been obtained; 
 6.1.2. entering this Agreement will not constitute a breach of any agreement, contract,
understanding or obligation, including such Party’s documents of incorporation; and 

  

			
		  	11

 6.1.3. it is a corporation duly organized, validly existing under the laws of the
jurisdiction of its organization and it has all necessary corporate power and authority to carry on its business as currently conducted or proposed to be conducted; and 

6.2. InveniAI’s Representations. InveniAI represents and warrants to Relief that: 

6.2.1. Neither the Platform nor the Accepted Product Concepts, nor Relief’s use of the Accepted Product Concepts for its intended
purposes will infringe or misappropriate a Third Party’s IP Right; 
 6.2.2. it has sufficient knowledge, asset and personnel
required to perform all of its obligations under this Agreement and use and furnish those knowledge, asset and personnel in performing its obligation under this Agreement, such as but not limited to the regular interactions in the JSC as defined in
this Agreement; 
 6.2.3. it will use its best professional principles and practices in accordance with normally accepted industry
standards in performing its obligation under this Agreement; and 
 6.2.4. it has sufficiently secured information, computing, cyber
and communication technology system to prevent any security breach or any other network accidents from occurring which is normally required to the industry that InveniAI belongs to. 

6.3. Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY
WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THE REPRESENTATIONS AND WARRANTIES AND DISCLAIMERS DESCRIBED IN THIS ARTICLE 6 ARE EXCLUSIVE AND SUPERSEDE ANY OTHER WARRANTY LIMITATIONS AND DISCLAIMERS GIVEN BY EITHER PARTY WITH RESPECT TO THE
SUBJECT MATTER CONTAINED HEREIN, WHETHER WRITTEN OR ORAL. EACH PARTY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND OF FITNESS FOR A PARTICULAR PURPOSE OR USE, NON-INFRINGEMENT, VALIDITY AND
ENFORCEABILITY OF PATENTS, OR THE PROSPECTS OR LIKELIHOOD OF DEVELOPMENT OR COMMERCIAL SUCCESS OF ANY ACCEPTED PRODUCT CONCEPT. 
 7.
TERM AND TERMINATION 
 7.1. Term. The term of this Agreement (the “Term”) will commence on
the Effective Date and continue in effect until InveniAI’s receipt of the last payment required by Relief under the Milestone Payments and the Commercialization Payments, unless earlier terminated in accordance with this Article 7 or extended
by the Parties by written agreement. 
 7.2. Termination for Cause. Each Party may terminate this Agreement before the
end of the Term upon written notice to the other Party if the other Party is in material breach of this Agreement, and such breaching Party has not cured such breach within ninety (90) days after notice is received by such non-breaching Party regarding such breach. Any such termination will become effective at the end of such ninety (90)-day period unless the breaching Party has cured any such
breach prior to the end of such period. 

  

			
		  	12

 7.3. Termination for Bankruptcy. Either Party may terminate this
Agreement if, at any time, the other Party files in any court or agency pursuant to any statute or regulation of any state or country a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a
receiver or trustee of the other Party or of substantially all of its assets; or if the other Party proposes a written agreement of composition or extension of substantially all of its debts; or if the other Party will be served with an involuntary
petition against it, filed in any insolvency proceeding, and such petition will not be dismissed within ninety (90) days after the filing thereof; or if the other Party will propose or be a party to any dissolution or liquidation; or if the
other Party will make an assignment of substantially all of its assets for the benefit of creditors. 
 7.4. Effect of
Termination. 
 7.4.1. The expiration or termination of this Agreement for any reason shall not (a) release InveniAI or
Relief from any liability which, at the time of such expiration or termination, has already accrued to such Party or which is attributable to a period prior to the effective date of such expiration or termination, (b) excuse Relief from its
payment obligations under Sections 5.2 and 5.3 without regard to whether the obligation accrues during or after the Term unless in case of Relief’s termination in accordance with Section 7.2, whereas Relief shall not be responsible to
perform its payment obligations after that InveniAI’s breach takes place, or (c) preclude InveniAI or Relief from pursuing all rights and remedies it may have under this Agreement, at law or in equity, with respect to breach of this
Agreement. 
 7.4.2. All rights and licenses granted under or pursuant to this Agreement are, and will otherwise be deemed to be, for
purposes of Bankruptcy Laws, licenses of rights to “intellectual property” as defined under the Bankruptcy Laws. If a case is commenced during the Term by or against a Party under Bankruptcy Laws then, unless and until this Agreement is
rejected as provided in such Bankruptcy Laws, such Party (in any capacity, including debtor-in-possession) and its Successors and assigns (including, a trustee) will
perform all of the obligations provided in this Agreement to be performed by such Party. If a case is commenced during the Term by or against a Party under the Bankruptcy Laws, this Agreement is rejected as provided in the Bankruptcy Laws and the
other Party elects to retain its rights hereunder as provided in the Bankruptcy Laws, then the Party subject to such case under the Bankruptcy Laws (in any capacity, including
debtor-in-possession) and its Successors and assigns (including, a Title 11 trustee), will provide to such other Party copies of all information necessary for such other
Party to prosecute, maintain and enjoy its rights under the terms of this Agreement promptly upon such other Party’s written request therefor. All rights, powers and remedies of the non-bankrupt Parties
as provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including, the Bankruptcy Laws) in the event of the commencement of a case by or against a
Party under the Bankruptcy Laws. It is the intention and understanding of the Parties to this Agreement that the rights granted to the Parties under this Section 7.4.2 are essential to the Parties’ respective businesses and the Parties
acknowledge that damages are not an adequate remedy. 

  

			
		  	13

 8. CONFIDENTIALITY 

8.1. Non-Disclosure Obligation. Other than as expressly authorized by this
Agreement or otherwise agreed to in writing by the Parties, the Parties agree that the Recipient undertakes to treat and maintain, and ensure that its Representatives will treat and maintain, in strict confidence and secrecy, Confidential
Information that is disclosed to it by the Discloser, will keep in confidence the existence and contents of this Agreement, and will not disclose, publish, or disseminate in any manner, any of Discloser’s Confidential Information to a Third
Party other than to those of its Representatives with a need to know the same for the purpose of performing its activities and obligations under this Agreement (the “Purpose”). Recipient will, in performing its duties and
obligations hereunder, use at least the same degree of care as it does with respect to its own confidential information of like importance but, in any event, at least reasonable care. Recipient agrees to be responsible for any use or disclosure of
Discloser’s Confidential Information to any of its said Representatives. For the avoidance of doubt, any concept, data, idea, right and other all information set forth in Section 4.1.1 shall be deemed as Relief’s Confidential
Information (Relief is the Discloser) and those in Section 4.1.2 shall be deemed as InveniAI’s Confidential Information (InveniAI is the Discloser). 

8.2. Exclusions. The undertakings and obligations under Sections 8.1, 8.3 and 8.5 will not apply to any part of the
Confidential Information which a Party can prove: 
 8.2.1. was known to the Recipient prior to disclosure by the Discloser as
evidenced by written records; 
 8.2.2. was generally available to the public prior to disclosure to the Recipient; 

8.2.3. is disclosed to Recipient by a Third Party who is not bound by any confidentiality obligation, having a legal right to make such
disclosure; 
 8.2.4. has become, through no act or failure to act on the part of the Recipient, public information or generally
available to the public; 
 8.2.5. is independently developed by the Recipient as evidenced by written records without reference to
or reliance upon the Discloser’s Confidential Information; or 
 8.3. The Recipient may disclose the Discloser’s
Confidential Information as required (and only to the extent of such requirement) to by law, court order, or governmental regulation (including securities laws and/or exchange regulations), provided that the Recipient to the extent permitted by law
gives the Discloser reasonable notice prior to any such disclosure and reasonably cooperates (at the Discloser’s expense) with the Discloser in obtaining a protective order or other suitable protection from disclosure (if available) with
respect to such Confidential Information. Notwithstanding the foregoing and for the sake of clarity, a Party shall have at all times the right to submit a copy of the present Agreement for disclosure purposes in accordance with securities laws
and/or exchange regulations, without receiving any prior written consent from the other Party. 

  

			
		  	14

 8.4. Irreparable Harm. The Parties acknowledge that each Party’s
respective Confidential Information is of special and unique significance to each of them and that any unauthorized disclosure or use of the Discloser’s Confidential Information could cause irreparable harm and significant injury to the
Discloser, which may be difficult to ascertain. Accordingly, any breach of this Agreement may entitle the aggrieved Party, in addition to any other right or remedy that it may have available to it by law or in equity, to remedies of injunction,
performance and other relief, including recourse in a court of law. 
 8.5. Notice. Each Party agrees to inform the
other Party of any breach or threatened breach of the provisions hereof by its Representatives. 
 8.6. Survival. The
provisions relating to confidentiality in this Article 8 will remain in effect during the Term and for a period of five (5) years after the expiration or termination of the Term. 

8.7. Return or Destruction of the Confidential Information. Upon termination of this Agreement for any reason, or upon
Discloser’s request at any time, Recipient will promptly return to Discloser or destroy, at the direction of Discloser, all originals and copies of any Confidential Information and destroy all information, records and materials developed
therefrom, provided, however, one copy may be retained in Recipient’s legal files for archival purposes as a means of determining any continuing obligation hereunder and the Recipient shall not be required to delete the Confidential Information
from back-up archival storage. Such destruction shall be certified in writing to Discloser. 
 9.
MISCELLANEOUS 
 9.1. Publicity. InveniAI, upon receipt of prior written approval of Relief, may issue
reasonable press releases, disclose the existence this Agreement and InveniAI’s relationship with Relief, and disclose to investors and potential investors, under confidentiality obligations consistent with Article 8, that it is providing or
has provided services using the Platform to Relief, provided that, in all cases, InveniAI does not disclose any Relief Confidential Information. Relief may issues press release in relation to the existence of this Agreement and Relief’s
relationship with InveniAI without receiving any prior written consent from InveniAI provided that, in all cases, Relief does not disclose any InveniAI Confidential Information. 

9.2. Indemnification. 

9.2.1. Indemnification of Relief. InveniAI shall defend, indemnify and hold harmless each of Relief and its Affiliates,
and the directors, officers, stockholders and employees of such entities and the Successors and assigns of any of the foregoing (the “Relief Indemnitees”) from and against any and all losses, liabilities, damages, penalties, fines,
costs and expenses (including reasonable attorneys’ fees and other expenses of litigation) (“Losses”) from any claims, actions, suits or proceedings brought by a Third Party (a “Third Party Claim”) incurred by
any Relief Indemnitee, arising from, or occurring as a result of (a) the willful misconduct or gross negligence of InveniAI or its Affiliates, (b) any breach of any representation or warranty made by InveniAI under this Agreement, or
(c) misappropriation of all or part of a Product Concept from a Third Party by InveniAI or its Affiliates; except in each case to the extent such Third Party Claims fall within the scope of the indemnification obligations of Relief set forth in
Section 9.2.2. 

  

			
		  	15

 9.2.2. Indemnification of InveniAI. Relief shall defend, indemnify and
hold harmless InveniAI, its Affiliates, and the directors, officers, stockholders and employees of such entities and the Successors and assigns of any of the foregoing (the “InveniAI Indemnitees”) from and against any and all Losses
from any Third Party Claim incurred by any InveniAI indemnitee, arising from or occurring as a result of (a) the willful misconduct or gross negligence of Relief or its Affiliates, (b) any breach of any representation or warranty made by
Relief under this Agreement, or (c) the use of any Product Concepts by Relief, including development or commercialization; except in each case to the extent such Third Party Claims fall within the scope of the indemnification obligations of
InveniAI set forth in Section 9.2.1. 
 9.2.3. Procedure. A Party that intends to claim indemnification under this
Section 9.2 shall promptly inform the indemnifying Party in writing of any Third Party Claim, in respect of which the indemnitee intends to claim such indemnification. The indemnified Party shall provide the indemnifying Party with reasonable
assistance, at the indemnifying Party’s expense, in connection with the defense of the Third Party Claim for which indemnity is being sought. The indemnitee may participate in and monitor such defense with counsel of its own choosing at its
sole expense; provided, however, the indemnitor shall have the right to assume and conduct the defense of the Third Party Claim with counsel of its choice. The indemnitor shall not settle any Third Party Claim without the prior written consent of
the indemnified Party, not to be unreasonably withheld or delayed, unless the settlement involves only the payment of money. So long as the indemnitor is actively defending the Third Party Claim in good faith, the indemnitee shall not settle any
such Third Party Claim without the prior written consent of the indemnifying Party. If the indemnitor does not assume and conduct the defense of the Third Party Claim as provided above, (a) the indemnitee may defend against, and consent to the
entry of any judgment or enter into any settlement with respect to the Third Party Claim in any manner the indemnitee may deem reasonably appropriate (and the indemnitee need not consult with, or obtain any consent from, the indemnitor in connection
therewith), and (b) the indemnitor will remain responsible to indemnify the indemnitee as provided in this Section 9.2. The failure to deliver written notice to the indemnitor within a reasonable time after the commencement of any action
with respect to a Third Party Claim shall only relieve the indemnitor of its indemnification obligations under this Section 9.2 if and to the extent the indemnitor is actually prejudiced thereby. 

9.3. Insurance. Each Party, at its own expense, shall maintain a program of insurance in amounts and types consistent
with industry standards for a company in a similar position to such Party during the Term. 
 9.4. Independent
Contractors. Each Party shall be and shall act as an independent contractor and not as an agent or partner of, or joint ventures with the other Party for any purpose and neither Party shall have the right, power, or authority to act or
create any obligation, express or implied, on behalf of the other Party. 
 9.5. Force Majeure. If the performance of
any part of this Agreement by either Party (other than making payments when due) is prevented, restricted, interfered with or delayed by any reason or cause beyond the reasonable control of such Party and which had been unforeseeable by such Party
(including fire, flood, earthquake, storm, embargo, power shortage or failure, acts of war, insurrection, riot, terrorism, strike, lockout or other labor disturbance, shortage of raw materials, regulatory hold, epidemic, pandemic, failure or default
of public utilities or common carriers, acts of God or any acts, omissions or delays in acting of the other Party) (a “Force Majeure Event”), the Party so affected will, upon giving written notice to the other Party, be excused from
such performance to the extent of such Force Majeure Event, provided that the affected Party will use its substantial efforts to avoid or remove such causes of non-performance and will continue performance
with the utmost dispatch whenever such causes are removed. Should the Force Majeure Event continue for a period of three (3) months, Relief shall have the right to terminate this Agreement on fifteen (15) days written notice. 

  

			
		  	16

 9.6. Limitation of Liability. EXCEPT FOR LIABILITY FOR BREACH OF
CONFIDENTIALITY PROVISIONS, GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT, NO PARTY OR ANY OF ITS AFFILIATES WILL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, INDIRECT, AGGRAVATED, EXEMPLARY OR PUNITIVE DAMAGES
(INCLUDING LOST PROFITS, BUSINESS OR GOODWILL) IN CONNECTION WITH THIS AGREEMENT, REGARDLESS OF WHETHER SUCH DAMAGES ARE FORESEEABLE, AND WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, OR
OTHERWISE, ARISING OUT OF THIS AGREEMENT. FOR THE SAKE OF CLARITY, NOTHING IN THIS AGREEMENT SHALL EXCLUDE OR LIMIT THE LIABILITY OF EITHER PARTY TO THE EXTENT THAT SUCH EXCLUSION OR LIMITATION IS NOT PERMITTED UNDER THE GOVERNING LAW DETERMINED AT
SECTION 9.9. 
 9.7. Dispute Resolution. The Parties recognize that disputes as to certain matters may from time to
time arise during the Term that relate to interpretation of a Party’s rights and/or obligations hereunder or any alleged breach of this Agreement. If the Parties cannot resolve any such dispute within thirty (30) days after written notice
of a dispute from one Party to another, either Party may, by written notice to the other Party, have such dispute referred to the President & CEO of InveniAI and the President and Representative Director or other senior management
designated by him/her of Relief (collectively, the “Senior Executives”). The Senior Executives shall negotiate in good faith to resolve the dispute within thirty (30) days. During such period of negotiations, any applicable
time periods under this Agreement shall be tolled. Such resolution, if any, by the Senior Executives shall be final and binding on the Parties. If the Senior Executives are unable to resolve the dispute within such time period, either Party may
submit such dispute for arbitration pursuant to Section 9.9, subject to the terms and conditions of this Agreement and the other agreements expressly contemplated hereunder. Notwithstanding anything in this Section 9.7 to the contrary,
InveniAI and Relief shall each have the right to apply to any court of competent jurisdiction for appropriate interim or provisional relief, as necessary to protect the rights or property of that Party, subject to Section 9.9. 

9.8. Notices. All notices, requests, demands, claims, and other communications permitted or required to be given under
this Agreement must be in writing and will be deemed duly given and received: (a) if personally delivered, when so delivered; (b) if sent through an express commercial delivery, upon receipt; or (c) if sent by email, on receipt of
acknowledgment from the intended recipient. 
  

			
	 To InveniAI:
	  	To Relief:
	 InveniAI LLC
	  	Relief Therapeutics Holding AG
	 2614 Boston Post Road
	  	Bâtiment F2/F3, Avenue de Sécheron 15,
	 Suite 33B, Guilford, CT 06437
	  	1202 Genève, Switzerland
	 Attention: Krishnan Nandabalan
	  	Attention: Jeremy Meinen
	 Email: knandabalan@inveniai.com
	  	Email: jeremy.meinen@relieftherapeutics.com

  

			
		  	17

 9.9. Governing Law; Arbitration. This Agreement shall be interpreted
and construed under the laws of the State of New York without regard to its conflicts of laws principles. If any dispute which cannot be resolved by the Senior Executives is referred for arbitration pursuant to Section 9.7, then such dispute
shall be finally settled by arbitration in accordance with the Rules of the American Arbitration Association then in effect. The place of Arbitration shall be the State of New York, USA and the language to be used in the arbitral proceedings shall
be English. Any award made hereunder may be entered into any court or tribunal having jurisdiction hereof. 
 9.10. Entire
Agreement. This Agreement constitutes the entire agreement among the Parties hereto with respect to the subject matter hereof and supersedes all prior understandings whether written or oral. This Agreement may be modified, amended or waived,
in whole or in part, only by written agreement of both Parties. 
 9.11. Severability. If any term or condition of this
Agreement is found to be invalid or unenforceable by any competent court, such term or condition shall be ineffective only to the extent that it is in contravention of applicable law, without invalidating the remaining terms and conditions. 

9.12. Assignment. 

9.12.1. InveniAI may assign this Agreement without the prior written consent of Relief: a) at any time to an Affiliate; b) starting
from the time of completion of the Development Program to a Third Party. 
 9.12.2. Relief may totally or partially assign this
Agreement to an Affiliate or any Third Party without prior written consent of InveniAI. 
 9.12.3. This Agreement shall be binding
upon and inure to the benefit of the Parties and their Successors and permitted assigns, provided that the assigning Party shall be obliged to cause its Successors or assignees to submit to the assigned Party a written undertaking that such
Successors or assigns shall perform and comply with any and all obligations under this Agreement. 
 9.13.
Construction. The section headings in this Agreement are for convenience of reference only and will in no way define, limit, extend, or describe the scope of intent of any provisions of this Agreement. Unless otherwise specifically
provided in this Agreement, the term “or” will not be deemed to be exclusive, and the terms “including,” “such as,” and words of similar import will not be deemed to limit the language preceding such term, but rather
will be deemed to mean “including without limitation.” This Agreement will be considered for all purposes as having been prepared through the joint efforts of the Parties; no presumption will apply in favor of either Party in the
interpretation of this Agreement or in the resolution of any ambiguity of any provision in this Agreement based on the preparation, substitution, submission, or other event of negotiation, drafting, or execution of this Agreement. 

  

			
		  	18

 9.14. Waiver of Breach. No delay or waiver by either Party of any
condition or term in any one or more instances will be construed as a further or continuing waiver of such condition or term or of another condition or term. 

9.15. Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to perform all
such other acts, as may be necessary or appropriate in order to carry out the Purposes and intent of this Agreement. 
 9.16.
Performance by Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party will agree to cause its Affiliates to perform such obligations. Any Party may contract with one or more of its
Affiliates to perform its obligations hereunder, provided that such Party will remain liable hereunder for the prompt payment and performance of all its respective obligations hereunder and any acts/omissions of such Affiliates as it relates to the
services. 
 9.17. Modification. No amendment or modification of any provision of this Agreement will be effective
unless in a prior writing signed by all Parties hereto. No provision of this Agreement will be varied, contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an agreement in writing and
signed by all Parties hereto. All purchase orders, acknowledgments and other business forms issued by either Party are for the convenience of the issuing Party, and will not modify or supplement this Agreement even if countersigned or otherwise
accepted by the other Party. 
 9.18. No Third Party Beneficiaries. No Person other than the Parties and their
respective permitted Successors and assigns hereunder will be deemed an intended beneficiary hereunder, nor have any right to enforce any obligation of any Party to this Agreement. 

9.19. Survival. Expiration or termination of this Agreement will not relieve the Parties of any rights or obligation
accruing prior to such expiration or termination. In addition, upon expiration or termination of this Agreement, all rights and obligations of the Parties under this Agreement will terminate, except those described in the following Sections and
Articles: Articles 1, 3, 4, 5, 6, 8 and 9 (excluding Section 9.1); Section 7.4. 
 9.20. Counterparts. This
Agreement may be executed in any number of counterparts each of which will be deemed an original, and all of which together will constitute one and the same instrument. This Agreement may be executed by .pdf or other electronically transmitted
signatures and such signatures shall be deemed to bind each Party hereto as if they were the original signatures. 
 Remainder of page
intentionally left blank. Signature page follows. 

  

			
		  	19

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective
Date. 
  

									
	INVENIAI LLC	 	 	 	RELIEF THERAPEUTICS HOLDING SA
					
	By:	 	/s/ Aman Kant	 		 	By:	 	/s/ Jeremy Meinen
	Name:	 	Aman Kant	 		 	Name:	 	Jeremy Meinen
	Title:	 	Chief Business Officer	 		 	Title:	 	VP Finance and Administration
	 	 	11/23/2021	 	 	 	 	 	11/23/2021

  

			
		  	20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]